evidence_id	assertion_id	disorder_id	disorder_name	source_file	section	section_index	path	evidence_index	reference	supports	evidence_source	snippet	explanation	raw_json
85	92	4	ATTR_Amyloidosis	ATTR_Amyloidosis.yaml	progression	0	evidence	0	PMID:35717381	PARTIAL		Symptomatic patients were predominantly male (71.4%) and had a mean ... age of symptom onset of 56.3 (17.8) years.	The study provides data on the age of symptom onset for symptomatic patients with ATTR amyloidosis, indicating a mean age of onset within the provided range for hereditary cases. However, it does not specify the exact onset age range for wild-type cases.	"{""explanation"": ""The study provides data on the age of symptom onset for symptomatic patients with ATTR amyloidosis, indicating a mean age of onset within the provided range for hereditary cases. However, it does not specify the exact onset age range for wild-type cases."", ""reference"": ""PMID:35717381"", ""snippet"": ""Symptomatic patients were predominantly male (71.4%) and had a mean ... age of symptom onset of 56.3 (17.8) years."", ""supports"": ""PARTIAL""}"
86	92	4	ATTR_Amyloidosis	ATTR_Amyloidosis.yaml	progression	0	evidence	1	PMID:30199915	PARTIAL		There is a significant increase in the number of patients with cardiac amyloidosis of the ATTR wild-type variety. These patients are often elderly males presenting with predominantly right sided heart failure.	This reference suggests that ATTR wild-type amyloidosis commonly affects elderly males, but it does not provide a specific onset age range of 60-80 years.	"{""explanation"": ""This reference suggests that ATTR wild-type amyloidosis commonly affects elderly males, but it does not provide a specific onset age range of 60-80 years."", ""reference"": ""PMID:30199915"", ""snippet"": ""There is a significant increase in the number of patients with cardiac amyloidosis of the ATTR wild-type variety. These patients are often elderly males presenting with predominantly right sided heart failure."", ""supports"": ""PARTIAL""}"
87	92	4	ATTR_Amyloidosis	ATTR_Amyloidosis.yaml	progression	0	evidence	2	PMID:31731233	PARTIAL		The prevalence of ATTR-wt was 5.8% (32 of the 556), with the prevalence increasing as a function of age. We identified an ATTR-wt-specific morbidity rate of 12.3% for patients over 80 years of age, while the prevalence among individuals over 90 years of age was 34.9%.	This study indicates that the prevalence of wild-type ATTR amyloidosis increases with age, particularly in those over 80 years. It supports the general notion that wild-type ATTR affects older individuals but does not provide a specific onset age range of 60-80 years.	"{""explanation"": ""This study indicates that the prevalence of wild-type ATTR amyloidosis increases with age, particularly in those over 80 years. It supports the general notion that wild-type ATTR affects older individuals but does not provide a specific onset age range of 60-80 years."", ""reference"": ""PMID:31731233"", ""snippet"": ""The prevalence of ATTR-wt was 5.8% (32 of the 556), with the prevalence increasing as a function of age. We identified an ATTR-wt-specific morbidity rate of 12.3% for patients over 80 years of age, while the prevalence among individuals over 90 years of age was 34.9%."", ""supports"": ""PARTIAL""}"
88	92	4	ATTR_Amyloidosis	ATTR_Amyloidosis.yaml	progression	0	evidence	3	PMID:25586652	NO_EVIDENCE		The aim of the study was to evaluate the clinical and genetic predictors of AA amyloidosis in patients with familial Mediterranean fever (FMF).	This study focuses on AA amyloidosis in familial Mediterranean fever and does not provide information on the age of onset for ATTR amyloidosis.	"{""explanation"": ""This study focuses on AA amyloidosis in familial Mediterranean fever and does not provide information on the age of onset for ATTR amyloidosis."", ""reference"": ""PMID:25586652"", ""snippet"": ""The aim of the study was to evaluate the clinical and genetic predictors of AA amyloidosis in patients with familial Mediterranean fever (FMF)."", ""supports"": ""NO_EVIDENCE""}"
264	231	9	Acquired Immunodeficiency Syndrome	Acquired_Immunodeficiency_Syndrome.yaml	progression	0	evidence	0	PMID:2922052	PARTIAL		A non-parametric implementation of this strategy produced an estimate with a median at 9.8 years...	The literature mentions a median incubation period of 9.8 years, which is within the range provided in the statement, but does not explicitly confirm the full range of 2-15 years.	"{""explanation"": ""The literature mentions a median incubation period of 9.8 years, which is within the range provided in the statement, but does not explicitly confirm the full range of 2-15 years."", ""reference"": ""PMID:2922052"", ""snippet"": ""A non-parametric implementation of this strategy produced an estimate with a median at 9.8 years..."", ""supports"": ""PARTIAL""}"
265	231	9	Acquired Immunodeficiency Syndrome	Acquired_Immunodeficiency_Syndrome.yaml	progression	0	evidence	1	PMID:3146367	PARTIAL		In the 10 patients for whom date of exposure to the virus could be established the incubation period was 11-28 days (median 14).	This reference provides a shorter incubation period (11-28 days) than the 2-15 years stated, suggesting the incubation period can vary widely depending on the study population, but does not directly support the 2-15 years range.	"{""explanation"": ""This reference provides a shorter incubation period (11-28 days) than the 2-15 years stated, suggesting the incubation period can vary widely depending on the study population, but does not directly support the 2-15 years range."", ""reference"": ""PMID:3146367"", ""snippet"": ""In the 10 patients for whom date of exposure to the virus could be established the incubation period was 11-28 days (median 14)."", ""supports"": ""PARTIAL""}"
266	231	9	Acquired Immunodeficiency Syndrome	Acquired_Immunodeficiency_Syndrome.yaml	progression	0	evidence	2	PMID:2996395	SUPPORT		The incubation period is long and few persons infected with human T-lymphotropic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV) have AIDS diagnosed within 2 to 5 years of infection.	This reference supports part of the statement (2-5 years), indicating an extended incubation period that falls within the provided range of 2-15 years.	"{""explanation"": ""This reference supports part of the statement (2-5 years), indicating an extended incubation period that falls within the provided range of 2-15 years."", ""reference"": ""PMID:2996395"", ""snippet"": ""The incubation period is long and few persons infected with human T-lymphotropic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV) have AIDS diagnosed within 2 to 5 years of infection."", ""supports"": ""SUPPORT""}"
366	271	10	Addison's Disease	Addisons_Disease.yaml	progression	0	evidence	0	PMID:12072049	NO_EVIDENCE		OBJECTIVE: Estimates of the prevalence of Addison's disease in Caucasians have varied from 39 to 117 per million. We have carried out an epidemiological study to obtain a confident point prevalence estimate in the Norwegian population for the end of 1999, and to find out whether the incidence is changing.	The study provides prevalence and incidence data but does not specify the age range for the onset of Addison's disease.	"{""explanation"": ""The study provides prevalence and incidence data but does not specify the age range for the onset of Addison's disease."", ""reference"": ""PMID:12072049"", ""snippet"": ""OBJECTIVE: Estimates of the prevalence of Addison's disease in Caucasians have varied from 39 to 117 per million. We have carried out an epidemiological study to obtain a confident point prevalence estimate in the Norwegian population for the end of 1999, and to find out whether the incidence is changing."", ""supports"": ""NO_EVIDENCE""}"
367	271	10	Addison's Disease	Addisons_Disease.yaml	progression	0	evidence	1	PMID:33143829	NO_EVIDENCE		OBJECTIVE: To determine the clinical presentation of Addison's disease in order to increase the awareness of presentation in Pakistani children.	The study focuses on the clinical presentation of Addison's disease in children, not in the age range of 30-50 years.	"{""explanation"": ""The study focuses on the clinical presentation of Addison's disease in children, not in the age range of 30-50 years."", ""reference"": ""PMID:33143829"", ""snippet"": ""OBJECTIVE: To determine the clinical presentation of Addison's disease in order to increase the awareness of presentation in Pakistani children."", ""supports"": ""NO_EVIDENCE""}"
368	271	10	Addison's Disease	Addisons_Disease.yaml	progression	0	evidence	2	PMID:23322510	NO_EVIDENCE		INTRODUCTION: Several studies have shown a reduced quality of life in patients with Addison's disease, but little is known about the potential influences.	The study discusses quality of life in Addison's disease patients but does not provide information on the age range of onset.	"{""explanation"": ""The study discusses quality of life in Addison's disease patients but does not provide information on the age range of onset."", ""reference"": ""PMID:23322510"", ""snippet"": ""INTRODUCTION: Several studies have shown a reduced quality of life in patients with Addison's disease, but little is known about the potential influences."", ""supports"": ""NO_EVIDENCE""}"
369	271	10	Addison's Disease	Addisons_Disease.yaml	progression	0	evidence	3	PMID:20400889	NO_EVIDENCE		INTRODUCTION: Little information is available on patients with adrenal insufficiency (AI) in regard to complaints before diagnosis, time until correct diagnosis, false diagnosis, and professional changes due to the diagnosis.	The study discusses the delay in diagnosis of adrenal insufficiency and related complaints but does not specify the age range for the onset of Addison's disease.	"{""explanation"": ""The study discusses the delay in diagnosis of adrenal insufficiency and related complaints but does not specify the age range for the onset of Addison's disease."", ""reference"": ""PMID:20400889"", ""snippet"": ""INTRODUCTION: Little information is available on patients with adrenal insufficiency (AI) in regard to complaints before diagnosis, time until correct diagnosis, false diagnosis, and professional changes due to the diagnosis."", ""supports"": ""NO_EVIDENCE""}"
370	271	10	Addison's Disease	Addisons_Disease.yaml	progression	0	evidence	4	PMID:31791082	NO_EVIDENCE		HISTORY AND CLINICAL FINDINGS: We report the case within a 22-year-old patient, initially seen because of fatigue, weight loss and discoloration of the skin.	The study discusses a case of a 22-year-old patient with Addison's disease, which does not fall within the age range of 30-50 years.	"{""explanation"": ""The study discusses a case of a 22-year-old patient with Addison's disease, which does not fall within the age range of 30-50 years."", ""reference"": ""PMID:31791082"", ""snippet"": ""HISTORY AND CLINICAL FINDINGS: We report the case within a 22-year-old patient, initially seen because of fatigue, weight loss and discoloration of the skin."", ""supports"": ""NO_EVIDENCE""}"
433	375	14	Ainhum	Ainhum.yaml	progression	0	evidence	0	PMID:12500788	SUPPORT	HUMAN_CLINICAL	frequently bilateral, with lesions in different stages.	Radiological survey reports lesions in different stages within patients.	"{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""Radiological survey reports lesions in different stages within patients."", ""reference"": ""PMID:12500788"", ""snippet"": ""frequently bilateral, with lesions in different stages."", ""supports"": ""SUPPORT""}"
779	603	24	Antiphospholipid Syndrome	Antiphospholipid_Syndrome.yaml	progression	0	evidence	0	PMID:34634966	PARTIAL		We subdivided patients into two groups: youth- (15-24 years) and adult-onset (over 24 years) and compared them regarding demographic characteristics, criteria and non-criteria manifestations, cardiovascular risk factors, and aPL status.	The reference supports that primary APS can indeed onset within the specified age range of 20-50, but it does not provide sufficient evidence to conclude that progression specifically occurs within this exact range.	"{""explanation"": ""The reference supports that primary APS can indeed onset within the specified age range of 20-50, but it does not provide sufficient evidence to conclude that progression specifically occurs within this exact range."", ""reference"": ""PMID:34634966"", ""snippet"": ""We subdivided patients into two groups: youth- (15-24 years) and adult-onset (over 24 years) and compared them regarding demographic characteristics, criteria and non-criteria manifestations, cardiovascular risk factors, and aPL status."", ""supports"": ""PARTIAL""}"
780	603	24	Antiphospholipid Syndrome	Antiphospholipid_Syndrome.yaml	progression	0	evidence	1	PMID:26125104	NO_EVIDENCE		Current innovative treatment options include novel oral anticoagulants and the complement inhibitor eculizumab.	While discussing treatment options for APS, this reference does not address the specific age range of 20-50 or the progression of primary APS.	"{""explanation"": ""While discussing treatment options for APS, this reference does not address the specific age range of 20-50 or the progression of primary APS."", ""reference"": ""PMID:26125104"", ""snippet"": ""Current innovative treatment options include novel oral anticoagulants and the complement inhibitor eculizumab."", ""supports"": ""NO_EVIDENCE""}"
827	641	26	Aromatase Deficiency	Aromatase_Deficiency.yaml	progression	0	evidence	0	PMID:19844120	SUPPORT		Placental aromatization of androgens protects the female fetus against the virilizing action of fetal androgens. After birth, the dual effect of aromatase deficiency, excessive androgens, and insufficient estrogens is responsible for a variable clinical picture.	The abstract explains that aromatase deficiency has implications from birth through adolescence, with effects noticeable from early childhood due to the imbalance of androgens and estrogens. This supports the statement that aromatase deficiency impacts this age range.	"{""explanation"": ""The abstract explains that aromatase deficiency has implications from birth through adolescence, with effects noticeable from early childhood due to the imbalance of androgens and estrogens. This supports the statement that aromatase deficiency impacts this age range."", ""reference"": ""PMID:19844120"", ""snippet"": ""Placental aromatization of androgens protects the female fetus against the virilizing action of fetal androgens. After birth, the dual effect of aromatase deficiency, excessive androgens, and insufficient estrogens is responsible for a variable clinical picture."", ""supports"": ""SUPPORT""}"
828	641	26	Aromatase Deficiency	Aromatase_Deficiency.yaml	progression	0	evidence	1	PMID:15815567	PARTIAL		Puberty is a dynamic period of physical growth, sexual maturation, and psychosocial achievement that generally begins between age 8 and 14 years.	While this reference discusses puberty and its onset, it does not specifically address aromatase deficiency or its progression from birth through adolescence.	"{""explanation"": ""While this reference discusses puberty and its onset, it does not specifically address aromatase deficiency or its progression from birth through adolescence."", ""reference"": ""PMID:15815567"", ""snippet"": ""Puberty is a dynamic period of physical growth, sexual maturation, and psychosocial achievement that generally begins between age 8 and 14 years."", ""supports"": ""PARTIAL""}"
1246	951	39	Bacterial meningitis	Bacterial_meningitis.yaml	progression	0	evidence	0	PMID:27367319	SUPPORT		If the infection is not controlled at the stage in which the bacterium is in the liver... a secondary bacteraemia can be developed and L. monocytogenes reaches the preferred sites transgressing the blood-brain barrier.	Describes bacteremia developing after initial mucosal infection, providing the bloodstream phase that precedes CNS invasion.	"{""explanation"": ""Describes bacteremia developing after initial mucosal infection, providing the bloodstream phase that precedes CNS invasion."", ""reference"": ""PMID:27367319"", ""snippet"": ""If the infection is not controlled at the stage in which the bacterium is in the liver... a secondary bacteraemia can be developed and L. monocytogenes reaches the preferred sites transgressing the blood-brain barrier."", ""supports"": ""SUPPORT""}"
1247	952	39	Bacterial meningitis	Bacterial_meningitis.yaml	progression	1	evidence	0	PMID:31805229	SUPPORT		Microbial penetration of the blood-brain barrier, a prerequisite for the development of bacterial meningitis, exploits specific host and bacterial factors as well as host cell signaling molecules.	Establishes BBB penetration as the required step to initiate meningitis.	"{""explanation"": ""Establishes BBB penetration as the required step to initiate meningitis."", ""reference"": ""PMID:31805229"", ""snippet"": ""Microbial penetration of the blood-brain barrier, a prerequisite for the development of bacterial meningitis, exploits specific host and bacterial factors as well as host cell signaling molecules."", ""supports"": ""SUPPORT""}"
1248	953	39	Bacterial meningitis	Bacterial_meningitis.yaml	progression	2	evidence	0	PMID:37544134	SUPPORT		In patients with acute bacterial meningitis CSF levels of IL-6, IL-8, IL-10, and TNF-α are significantly increased than in serum.	Elevated CSF cytokines reflect heavy intrathecal bacterial load and immune activation consistent with rapid CSF proliferation.	"{""explanation"": ""Elevated CSF cytokines reflect heavy intrathecal bacterial load and immune activation consistent with rapid CSF proliferation."", ""reference"": ""PMID:37544134"", ""snippet"": ""In patients with acute bacterial meningitis CSF levels of IL-6, IL-8, IL-10, and TNF-α are significantly increased than in serum."", ""supports"": ""SUPPORT""}"
1249	954	39	Bacterial meningitis	Bacterial_meningitis.yaml	progression	3	evidence	0	PMID:39116800	SUPPORT		after the disruption of the blood-brain barrier (BBB), these pathogens trigger several inflammatory pathways including Toll-Like Receptor (TLR) signaling... that lead to pro-inflammatory cascade and subsequent cytokine release including interleukine (IL)-1β, tumor necrosis factor(TNF)-α, IL-6, IL-8, chemokine (C-X-C motif) ligand 1 (CXCL1) along with other mediators, leading to neuroinflammation.	Shows TLR-driven innate signaling and cytokine release after BBB breach.	"{""explanation"": ""Shows TLR-driven innate signaling and cytokine release after BBB breach."", ""reference"": ""PMID:39116800"", ""snippet"": ""after the disruption of the blood-brain barrier (BBB), these pathogens trigger several inflammatory pathways including Toll-Like Receptor (TLR) signaling... that lead to pro-inflammatory cascade and subsequent cytokine release including interleukine (IL)-1β, tumor necrosis factor(TNF)-α, IL-6, IL-8, chemokine (C-X-C motif) ligand 1 (CXCL1) along with other mediators, leading to neuroinflammation."", ""supports"": ""SUPPORT""}"
1250	955	39	Bacterial meningitis	Bacterial_meningitis.yaml	progression	4	evidence	0	PMID:39116800	SUPPORT		these pathogens trigger several inflammatory pathways including Toll-Like Receptor (TLR) signaling... NF-κB signaling and many other pathways that lead to pro-inflammatory cascade and subsequent cytokine release including interleukine (IL)-1β, tumor necrosis factor(TNF)-α, IL-6, IL-8, chemokine (C-X-C motif) ligand 1 (CXCL1) along with other mediators, leading to neuroinflammation.	Details inflammatory signaling cascades that drive barrier injury and neuroinflammation.	"{""explanation"": ""Details inflammatory signaling cascades that drive barrier injury and neuroinflammation."", ""reference"": ""PMID:39116800"", ""snippet"": ""these pathogens trigger several inflammatory pathways including Toll-Like Receptor (TLR) signaling... NF-κB signaling and many other pathways that lead to pro-inflammatory cascade and subsequent cytokine release including interleukine (IL)-1β, tumor necrosis factor(TNF)-α, IL-6, IL-8, chemokine (C-X-C motif) ligand 1 (CXCL1) along with other mediators, leading to neuroinflammation."", ""supports"": ""SUPPORT""}"
1251	956	39	Bacterial meningitis	Bacterial_meningitis.yaml	progression	5	evidence	0	PMID:2498090	SUPPORT		presence in the cerebrospinal fluid is associated with the induction of inflammation and with the development of brain edema and increased intracranial pressure.	Links CSF bacterial products to brain edema and raised intracranial pressure, driving neurological complications.	"{""explanation"": ""Links CSF bacterial products to brain edema and raised intracranial pressure, driving neurological complications."", ""reference"": ""PMID:2498090"", ""snippet"": ""presence in the cerebrospinal fluid is associated with the induction of inflammation and with the development of brain edema and increased intracranial pressure."", ""supports"": ""SUPPORT""}"
1471	1163	47	Bird Fancier's Lung	Bird_Fanciers_Lung.yaml	progression	0	evidence	0	PMID:6761066	SUPPORT	HUMAN_CLINICAL	Symptoms usually begin 4 to 6 hr after exposure to large quantities of causative organic dust.	The review describes rapid onset after exposure in acute disease.	"{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""The review describes rapid onset after exposure in acute disease."", ""reference"": ""PMID:6761066"", ""snippet"": ""Symptoms usually begin 4 to 6 hr after exposure to large quantities of causative organic dust."", ""supports"": ""SUPPORT""}"
1472	1164	47	Bird Fancier's Lung	Bird_Fanciers_Lung.yaml	progression	1	evidence	0	PMID:6761066	SUPPORT	HUMAN_CLINICAL	Chronically, these diseases may present with the gradual onset of cough, dyspnea on exertion, fatigue, anorexia, and weight loss which may progress to pulmonary fibrosis or severe pulmonary insufficiency.	The review notes gradual onset and progression to fibrosis.	"{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""The review notes gradual onset and progression to fibrosis."", ""reference"": ""PMID:6761066"", ""snippet"": ""Chronically, these diseases may present with the gradual onset of cough, dyspnea on exertion, fatigue, anorexia, and weight loss which may progress to pulmonary fibrosis or severe pulmonary insufficiency."", ""supports"": ""SUPPORT""}"
1719	1450	61	Cholera	Cholera.yaml	progression	0	evidence	0	PMID:23201968	PARTIAL		We estimate the median incubation period of toxigenic cholera to be 1.4 days (95% CI, 1.3-1.6). Five percent of cholera cases will develop symptoms by 0.5 days (95% CI 0.4-0.5), and 95% by 4.4 days (95% CI 3.9-5.0) after infection.	The literature describes an incubation period median of 1.4 days and a window from 0.5 days to 4.4 days for symptom onset, which is consistent with a portion of the stated range but does not completely align.	"{""explanation"": ""The literature describes an incubation period median of 1.4 days and a window from 0.5 days to 4.4 days for symptom onset, which is consistent with a portion of the stated range but does not completely align."", ""reference"": ""PMID:23201968"", ""snippet"": ""We estimate the median incubation period of toxigenic cholera to be 1.4 days (95% CI, 1.3-1.6). Five percent of cholera cases will develop symptoms by 0.5 days (95% CI 0.4-0.5), and 95% by 4.4 days (95% CI 3.9-5.0) after infection."", ""supports"": ""PARTIAL""}"
1720	1451	61	Cholera	Cholera.yaml	progression	1	evidence	0	PMID:1465231	NO_EVIDENCE		Cholera is a diarrheal disease that results from colonization of the small intestine by the Vibrio cholerae organism. The disease is spread primarily by means of fecal contamination of drinking water and may begin with the sudden onset of profuse, watery diarrhea. Vomiting, rapid dehydration, acidosis, muscular cramps and circulatory collapse are other prominent features of severe cholera.	The reference discusses the symptoms and features of cholera but does not provide information specific to the progression phase or the duration of the prodromal phase.	"{""explanation"": ""The reference discusses the symptoms and features of cholera but does not provide information specific to the progression phase or the duration of the prodromal phase."", ""reference"": ""PMID:1465231"", ""snippet"": ""Cholera is a diarrheal disease that results from colonization of the small intestine by the Vibrio cholerae organism. The disease is spread primarily by means of fecal contamination of drinking water and may begin with the sudden onset of profuse, watery diarrhea. Vomiting, rapid dehydration, acidosis, muscular cramps and circulatory collapse are other prominent features of severe cholera."", ""supports"": ""NO_EVIDENCE""}"
1721	1451	61	Cholera	Cholera.yaml	progression	1	evidence	1	PMID:23201968	NO_EVIDENCE		We estimate the median incubation period of toxigenic cholera to be 1.4 days (95% CI, 1.3-1.6). Five percent of cholera cases will develop symptoms by 0.5 days (95% CI 0.4-0.5), and 95% by 4.4 days (95% CI 3.9-5.0) after infection.	This reference provides data on the incubation period of cholera but does not detail the duration of the prodromal phase or early symptoms specific to hours.	"{""explanation"": ""This reference provides data on the incubation period of cholera but does not detail the duration of the prodromal phase or early symptoms specific to hours."", ""reference"": ""PMID:23201968"", ""snippet"": ""We estimate the median incubation period of toxigenic cholera to be 1.4 days (95% CI, 1.3-1.6). Five percent of cholera cases will develop symptoms by 0.5 days (95% CI 0.4-0.5), and 95% by 4.4 days (95% CI 3.9-5.0) after infection."", ""supports"": ""NO_EVIDENCE""}"
1722	1451	61	Cholera	Cholera.yaml	progression	1	evidence	2	PMID:38702080	NO_EVIDENCE		The study found results consistent with previous AWD outbreaks in developing countries like Yemen, Nigeria and Lebanon.	The reference is focused on acute watery diarrhea during cholera outbreaks but does not offer details on the prodromal phase duration or specific early symptoms.	"{""explanation"": ""The reference is focused on acute watery diarrhea during cholera outbreaks but does not offer details on the prodromal phase duration or specific early symptoms."", ""reference"": ""PMID:38702080"", ""snippet"": ""The study found results consistent with previous AWD outbreaks in developing countries like Yemen, Nigeria and Lebanon."", ""supports"": ""NO_EVIDENCE""}"
1723	1451	61	Cholera	Cholera.yaml	progression	1	evidence	3	PMID:37580033	NO_EVIDENCE		From May 4, 2014 through November 30, 2021, we enrolled 51,414 suspected cases from our sentinel surveillance sites.	The study is about national cholera surveillance and does not address the specific progression or the prodromal phase duration in hours.	"{""explanation"": ""The study is about national cholera surveillance and does not address the specific progression or the prodromal phase duration in hours."", ""reference"": ""PMID:37580033"", ""snippet"": ""From May 4, 2014 through November 30, 2021, we enrolled 51,414 suspected cases from our sentinel surveillance sites."", ""supports"": ""NO_EVIDENCE""}"
1724	1451	61	Cholera	Cholera.yaml	progression	1	evidence	4	PMID:18704085	NO_EVIDENCE		This is true for cholera, a pandemic bacterial disease, where estimates of the ratio of asymptomatic to symptomatic infections have ranged from 3 to 100 (refs 1-5).	This study discusses asymptomatic infections and their implications but does not provide detailed information on early symptoms duration in hours.	"{""explanation"": ""This study discusses asymptomatic infections and their implications but does not provide detailed information on early symptoms duration in hours."", ""reference"": ""PMID:18704085"", ""snippet"": ""This is true for cholera, a pandemic bacterial disease, where estimates of the ratio of asymptomatic to symptomatic infections have ranged from 3 to 100 (refs 1-5)."", ""supports"": ""NO_EVIDENCE""}"
1725	1451	61	Cholera	Cholera.yaml	progression	1	evidence	5	PMID:29165706	NO_EVIDENCE		We investigated singular Danish cholera epidemics (in 1853) to elucidate epidemiological parameters and modes of spread.	The reference concerns historical cholera epidemics and their transmission but does not address the duration of the prodromal phase or early symptoms.	"{""explanation"": ""The reference concerns historical cholera epidemics and their transmission but does not address the duration of the prodromal phase or early symptoms."", ""reference"": ""PMID:29165706"", ""snippet"": ""We investigated singular Danish cholera epidemics (in 1853) to elucidate epidemiological parameters and modes of spread."", ""supports"": ""NO_EVIDENCE""}"
1726	1451	61	Cholera	Cholera.yaml	progression	1	evidence	6	PMID:21150867	NO_EVIDENCE		As of December 3, MSPP reported 91,770 cases of cholera from all 10 departments and the capital city of Port-au-Prince.	This study details the cholera outbreak in Haiti but does not provide specific information on the early symptoms duration in hours.	"{""explanation"": ""This study details the cholera outbreak in Haiti but does not provide specific information on the early symptoms duration in hours."", ""reference"": ""PMID:21150867"", ""snippet"": ""As of December 3, MSPP reported 91,770 cases of cholera from all 10 departments and the capital city of Port-au-Prince."", ""supports"": ""NO_EVIDENCE""}"
1727	1451	61	Cholera	Cholera.yaml	progression	1	evidence	7	PMID:8548982	NO_EVIDENCE		The clinical manifestations of cholera and the pathophysiology of the toxin-induced diarrhea are reviewed.	This review on cholera's clinical manifestations does not offer specifics on the duration of the prodromal phase or early symptoms in hours.	"{""explanation"": ""This review on cholera's clinical manifestations does not offer specifics on the duration of the prodromal phase or early symptoms in hours."", ""reference"": ""PMID:8548982"", ""snippet"": ""The clinical manifestations of cholera and the pathophysiology of the toxin-induced diarrhea are reviewed."", ""supports"": ""NO_EVIDENCE""}"
1728	1451	61	Cholera	Cholera.yaml	progression	1	evidence	8	PMID:23622872	NO_EVIDENCE		We identified 281 Vibrio cholerae non-O1, non-O139 strains from patients with diarrhea in Kolkata, India. Cholera-like diarrhea was the major symptom (66.0%); some patients (20.3%) had severe dehydration.	The focus is on non-O1, non-O139 Vibrio cholerae strains and does not provide information on the prodromal phase duration or early symptoms in hours.	"{""explanation"": ""The focus is on non-O1, non-O139 Vibrio cholerae strains and does not provide information on the prodromal phase duration or early symptoms in hours."", ""reference"": ""PMID:23622872"", ""snippet"": ""We identified 281 Vibrio cholerae non-O1, non-O139 strains from patients with diarrhea in Kolkata, India. Cholera-like diarrhea was the major symptom (66.0%); some patients (20.3%) had severe dehydration."", ""supports"": ""NO_EVIDENCE""}"
1729	1452	61	Cholera	Cholera.yaml	progression	2	evidence	0	PMID:23201968	SUPPORT		We estimate the median incubation period of toxigenic cholera to be 1.4 days (95% CI, 1.3-1.6). Five percent of cholera cases will develop symptoms by 0.5 days (95% CI 0.4-0.5), and 95% by 4.4 days (95% CI 3.9-5.0) after infection.	This reference supports the rapid progression of cholera, stating that symptoms can develop within half a day to around 4-5 days after infection.	"{""explanation"": ""This reference supports the rapid progression of cholera, stating that symptoms can develop within half a day to around 4-5 days after infection."", ""reference"": ""PMID:23201968"", ""snippet"": ""We estimate the median incubation period of toxigenic cholera to be 1.4 days (95% CI, 1.3-1.6). Five percent of cholera cases will develop symptoms by 0.5 days (95% CI 0.4-0.5), and 95% by 4.4 days (95% CI 3.9-5.0) after infection."", ""supports"": ""SUPPORT""}"
1730	1453	61	Cholera	Cholera.yaml	progression	3	evidence	0	PMID:37769103	NO_EVIDENCE			The abstract does not provide specific information about the progression of cholera within the first 24-48 hours.	"{""explanation"": ""The abstract does not provide specific information about the progression of cholera within the first 24-48 hours."", ""reference"": ""PMID:37769103"", ""snippet"": """", ""supports"": ""NO_EVIDENCE""}"
1731	1453	61	Cholera	Cholera.yaml	progression	3	evidence	1	PMID:8548982	NO_EVIDENCE			The abstract covers the epidemiology and general clinical manifestations but does not detail the progression specific to the first 24–48 hours.	"{""explanation"": ""The abstract covers the epidemiology and general clinical manifestations but does not detail the progression specific to the first 24–48 hours."", ""reference"": ""PMID:8548982"", ""snippet"": """", ""supports"": ""NO_EVIDENCE""}"
1732	1453	61	Cholera	Cholera.yaml	progression	3	evidence	2	PMID:31668817	NO_EVIDENCE			The abstract reviews case management of cholera but does not provide information specifically regarding the initial 24-48 hours.	"{""explanation"": ""The abstract reviews case management of cholera but does not provide information specifically regarding the initial 24-48 hours."", ""reference"": ""PMID:31668817"", ""snippet"": """", ""supports"": ""NO_EVIDENCE""}"
1733	1453	61	Cholera	Cholera.yaml	progression	3	evidence	3	PMID:20135270	NO_EVIDENCE			The abstract estimates the prevalence of cholera in pediatric patients with acute dehydrating diarrhea but does not specify the time frame within the first 24-48 hours.	"{""explanation"": ""The abstract estimates the prevalence of cholera in pediatric patients with acute dehydrating diarrhea but does not specify the time frame within the first 24-48 hours."", ""reference"": ""PMID:20135270"", ""snippet"": """", ""supports"": ""NO_EVIDENCE""}"
1734	1454	61	Cholera	Cholera.yaml	progression	4	evidence	0	PMID:23201968	NO_EVIDENCE		We estimate the median incubation period of toxigenic cholera to be 1.4 days (95% CI, 1.3-1.6). Five percent of cholera cases will develop symptoms by 0.5 days (95% CI 0.4-0.5), and 95% by 4.4 days (95% CI 3.9-5.0) after infection.	While this paper provides information on the incubation period of cholera rather than the duration of symptoms, it indirectly suggests that the symptom onset and duration can vary significantly.	"{""explanation"": ""While this paper provides information on the incubation period of cholera rather than the duration of symptoms, it indirectly suggests that the symptom onset and duration can vary significantly."", ""reference"": ""PMID:23201968"", ""snippet"": ""We estimate the median incubation period of toxigenic cholera to be 1.4 days (95% CI, 1.3-1.6). Five percent of cholera cases will develop symptoms by 0.5 days (95% CI 0.4-0.5), and 95% by 4.4 days (95% CI 3.9-5.0) after infection."", ""supports"": ""NO_EVIDENCE""}"
1735	1454	61	Cholera	Cholera.yaml	progression	4	evidence	1	PMID:31668817	NO_EVIDENCE		Cholera can be effectively managed in the majority of cases with oral rehydration solution alone. Up to one third of patients present with severe dehydration, which can be diagnosed clinically, and will require rapid intravenous rehydration...	This reference focuses more on the treatment and management of cholera rather than the progression and duration of symptoms.	"{""explanation"": ""This reference focuses more on the treatment and management of cholera rather than the progression and duration of symptoms."", ""reference"": ""PMID:31668817"", ""snippet"": ""Cholera can be effectively managed in the majority of cases with oral rehydration solution alone. Up to one third of patients present with severe dehydration, which can be diagnosed clinically, and will require rapid intravenous rehydration..."", ""supports"": ""NO_EVIDENCE""}"
1736	1455	61	Cholera	Cholera.yaml	progression	5	evidence	0	PMID:23201968	PARTIAL		Five percent of cholera cases will develop symptoms by 0.5 days (95% CI 0.4-0.5), and 95% by 4.4 days (95% CI 3.9-5.0) after infection.	The reference provides information on the incubation period but not on the overall progression of the disease or the recovery phase.	"{""explanation"": ""The reference provides information on the incubation period but not on the overall progression of the disease or the recovery phase."", ""reference"": ""PMID:23201968"", ""snippet"": ""Five percent of cholera cases will develop symptoms by 0.5 days (95% CI 0.4-0.5), and 95% by 4.4 days (95% CI 3.9-5.0) after infection."", ""supports"": ""PARTIAL""}"
1737	1455	61	Cholera	Cholera.yaml	progression	5	evidence	1	PMID:10414380	PARTIAL		Nine (69.2%) of the convalescents had positive faecal cultures for periods ranging from two weeks to more than seven months.	This literature supports that bacteria can be shed in stool during the convalescent period but does not provide a comprehensive view of the full disease progression or typical duration of symptoms.	"{""explanation"": ""This literature supports that bacteria can be shed in stool during the convalescent period but does not provide a comprehensive view of the full disease progression or typical duration of symptoms."", ""reference"": ""PMID:10414380"", ""snippet"": ""Nine (69.2%) of the convalescents had positive faecal cultures for periods ranging from two weeks to more than seven months."", ""supports"": ""PARTIAL""}"
1738	1456	61	Cholera	Cholera.yaml	progression	6	evidence	0	PMID:5300876	SUPPORT		The duration of the carrier state among 19 household carriers isolated for examination varied from 5 to 19 days.	This literature provides data on the duration of the carrier state, indicating that some individuals can carry and shed the bacteria for several days, which supports the statement regarding the duration of asymptomatic carriage.	"{""explanation"": ""This literature provides data on the duration of the carrier state, indicating that some individuals can carry and shed the bacteria for several days, which supports the statement regarding the duration of asymptomatic carriage."", ""reference"": ""PMID:5300876"", ""snippet"": ""The duration of the carrier state among 19 household carriers isolated for examination varied from 5 to 19 days."", ""supports"": ""SUPPORT""}"
1739	1456	61	Cholera	Cholera.yaml	progression	6	evidence	1	PMID:8373550	SUPPORT		There are also cases of cholera where victims do not show any symptoms of it, that is asymptomatic carriers.	The statement about asymptomatic carriage is supported, as the literature confirms the existence of asymptomatic carriers who can harbor the bacteria for varying periods.	"{""explanation"": ""The statement about asymptomatic carriage is supported, as the literature confirms the existence of asymptomatic carriers who can harbor the bacteria for varying periods."", ""reference"": ""PMID:8373550"", ""snippet"": ""There are also cases of cholera where victims do not show any symptoms of it, that is asymptomatic carriers."", ""supports"": ""SUPPORT""}"
1740	1456	61	Cholera	Cholera.yaml	progression	6	evidence	2	PMID:32529415	PARTIAL		They indicate the existence of bacteria and asymptomatic individuals in the population of Senegal at any single time for the duration of collection of the data.	The statement is partially supported as the literature indicates the presence of asymptomatic carriers in the population, although it does not specify the exact duration of carriage.	"{""explanation"": ""The statement is partially supported as the literature indicates the presence of asymptomatic carriers in the population, although it does not specify the exact duration of carriage."", ""reference"": ""PMID:32529415"", ""snippet"": ""They indicate the existence of bacteria and asymptomatic individuals in the population of Senegal at any single time for the duration of collection of the data."", ""supports"": ""PARTIAL""}"
1741	1456	61	Cholera	Cholera.yaml	progression	6	evidence	3	PMID:28483382	NO_EVIDENCE		Information on human settlements and host mobility on waterways along which pathogens and hosts disperse, and relevant hydroclimatological processes, can be acquired remotely and included in spatially explicit mathematical models of disease transmission.	This study focuses on drivers of cholera transmission using spatially explicit models and does not provide information on the duration of asymptomatic carriage.	"{""explanation"": ""This study focuses on drivers of cholera transmission using spatially explicit models and does not provide information on the duration of asymptomatic carriage."", ""reference"": ""PMID:28483382"", ""snippet"": ""Information on human settlements and host mobility on waterways along which pathogens and hosts disperse, and relevant hydroclimatological processes, can be acquired remotely and included in spatially explicit mathematical models of disease transmission."", ""supports"": ""NO_EVIDENCE""}"
1742	1456	61	Cholera	Cholera.yaml	progression	6	evidence	4	PMID:34670655	NO_EVIDENCE		This study describes the apparent discontinuation of cholera transmission in Haiti since February 2019.	This study discusses cholera transmission cessation in Haiti and does not address the duration of asymptomatic carriage.	"{""explanation"": ""This study discusses cholera transmission cessation in Haiti and does not address the duration of asymptomatic carriage."", ""reference"": ""PMID:34670655"", ""snippet"": ""This study describes the apparent discontinuation of cholera transmission in Haiti since February 2019."", ""supports"": ""NO_EVIDENCE""}"
1743	1456	61	Cholera	Cholera.yaml	progression	6	evidence	5	PMID:23201968	NO_EVIDENCE		The incubation period did not differ by a clinically significant margin between strains (except O1 El Tor Ogawa).	This review focuses on the incubation period of cholera and does not discuss the duration of asymptomatic carriage.	"{""explanation"": ""This review focuses on the incubation period of cholera and does not discuss the duration of asymptomatic carriage."", ""reference"": ""PMID:23201968"", ""snippet"": ""The incubation period did not differ by a clinically significant margin between strains (except O1 El Tor Ogawa)."", ""supports"": ""NO_EVIDENCE""}"
1744	1456	61	Cholera	Cholera.yaml	progression	6	evidence	6	PMID:22461716	NO_EVIDENCE		About 1.4 billion people are at risk for cholera in endemic countries.	This study estimates the global burden of cholera and does not provide information on the duration of asymptomatic carriage.	"{""explanation"": ""This study estimates the global burden of cholera and does not provide information on the duration of asymptomatic carriage."", ""reference"": ""PMID:22461716"", ""snippet"": ""About 1.4 billion people are at risk for cholera in endemic countries."", ""supports"": ""NO_EVIDENCE""}"
1876	1604	67	Chronic_Obstructive_Pulmonary_Disease	Chronic_Obstructive_Pulmonary_Disease.yaml	progression	0	evidence	0	PMID:26154786	PARTIAL		Among 657 persons who had an FEV1 of less than 80% of the predicted value before 40 years of age, 174 (26%) had COPD after 22 years of observation, whereas among 2207 persons who had a baseline FEV1 of at least 80% of the predicted value before 40 years of age, 158 (7%) had COPD after 22 years of observation.	The literature suggests that COPD can develop in individuals with low FEV1 before the age of 40. While this supports the idea that COPD typically begins in individuals over 40, it also indicates that it can start earlier in some cases.	"{""explanation"": ""The literature suggests that COPD can develop in individuals with low FEV1 before the age of 40. While this supports the idea that COPD typically begins in individuals over 40, it also indicates that it can start earlier in some cases."", ""reference"": ""PMID:26154786"", ""snippet"": ""Among 657 persons who had an FEV1 of less than 80% of the predicted value before 40 years of age, 174 (26%) had COPD after 22 years of observation, whereas among 2207 persons who had a baseline FEV1 of at least 80% of the predicted value before 40 years of age, 158 (7%) had COPD after 22 years of observation."", ""supports"": ""PARTIAL""}"
1877	1604	67	Chronic_Obstructive_Pulmonary_Disease	Chronic_Obstructive_Pulmonary_Disease.yaml	progression	0	evidence	1	PMID:19934351	SUPPORT		There is growing evidence of higher prevalence of chronic obstructive pulmonary disease (COPD) in the elderly. Age-associated changes in the structure and function of the lung may increase a pathogenetic susceptibility to COPD.	This reference supports the statement that COPD typically begins in individuals over the age of 40, particularly due to age-associated changes in lung structure and function.	"{""explanation"": ""This reference supports the statement that COPD typically begins in individuals over the age of 40, particularly due to age-associated changes in lung structure and function."", ""reference"": ""PMID:19934351"", ""snippet"": ""There is growing evidence of higher prevalence of chronic obstructive pulmonary disease (COPD) in the elderly. Age-associated changes in the structure and function of the lung may increase a pathogenetic susceptibility to COPD."", ""supports"": ""SUPPORT""}"
2109	1852	77	Crohn Disease	Crohn_Disease.yaml	progression	0	evidence	0	PMID:33587489	SUPPORT		Patients were divided into a derivation (80%) cohort and a validation (20%) cohort. The primary outcome was progressive disease... In our final model, age at diagnosis older than 60 years was significantly associated with a lower risk of developing progressive disease... In patients with CD.	The study indicates that younger patients, particularly those aged less than 60 years, are at higher risk of developing progressive Crohn's disease.	"{""explanation"": ""The study indicates that younger patients, particularly those aged less than 60 years, are at higher risk of developing progressive Crohn's disease."", ""reference"": ""PMID:33587489"", ""snippet"": ""Patients were divided into a derivation (80%) cohort and a validation (20%) cohort. The primary outcome was progressive disease... In our final model, age at diagnosis older than 60 years was significantly associated with a lower risk of developing progressive disease... In patients with CD."", ""supports"": ""SUPPORT""}"
2110	1852	77	Crohn Disease	Crohn_Disease.yaml	progression	0	evidence	1	PMID:37384664	REFUTE		Logistic regression analysis of the initial characteristics showed that the age at diagnosis, gender, initial location and initial extra-intestinal manifestation are not associated with the progression of the disease.	This study states that the progression of Crohn's disease is not linked to the initial age of diagnosis among children and adolescents.	"{""explanation"": ""This study states that the progression of Crohn's disease is not linked to the initial age of diagnosis among children and adolescents."", ""reference"": ""PMID:37384664"", ""snippet"": ""Logistic regression analysis of the initial characteristics showed that the age at diagnosis, gender, initial location and initial extra-intestinal manifestation are not associated with the progression of the disease."", ""supports"": ""REFUTE""}"
2111	1852	77	Crohn Disease	Crohn_Disease.yaml	progression	0	evidence	2	PMID:37266570	PARTIAL		The best predictive model (PREDICT-EPIMAD) included the location at diagnosis, pANCA, and 6 single nucleotide polymorphisms. This model showed good discrimination... Decision curve analysis confirmed the clinical utility of the model.	Though the exact age range of 15-35 is not specifically discussed, the predictive model includes various factors that can affect disease progression, which might encompass age-related variations.	"{""explanation"": ""Though the exact age range of 15-35 is not specifically discussed, the predictive model includes various factors that can affect disease progression, which might encompass age-related variations."", ""reference"": ""PMID:37266570"", ""snippet"": ""The best predictive model (PREDICT-EPIMAD) included the location at diagnosis, pANCA, and 6 single nucleotide polymorphisms. This model showed good discrimination... Decision curve analysis confirmed the clinical utility of the model."", ""supports"": ""PARTIAL""}"
2112	1852	77	Crohn Disease	Crohn_Disease.yaml	progression	0	evidence	3	PMID:28051217	NO_EVIDENCE		Our aim was to identify the phenotype evolution of Crohn's disease over time according to the Montreal Classification and to precise predictive factors of the need for immunosuppressant treatment or surgery... without association with age, sex or smoking habits.	This study did not find evidence associating age with the progression of Crohn's disease, focusing instead on phenotype and specific disease markers.	"{""explanation"": ""This study did not find evidence associating age with the progression of Crohn's disease, focusing instead on phenotype and specific disease markers."", ""reference"": ""PMID:28051217"", ""snippet"": ""Our aim was to identify the phenotype evolution of Crohn's disease over time according to the Montreal Classification and to precise predictive factors of the need for immunosuppressant treatment or surgery... without association with age, sex or smoking habits."", ""supports"": ""NO_EVIDENCE""}"
2401	2266	100	Ebola Virus Disease (EVD)	Ebola_Virus_Disease_EVD.yaml	progression	0	evidence	0	PMID:25763588	SUPPORT		The incubation period of the disease ranges from 2 to 21 days.	The literature specifies that the incubation period for Ebola virus disease ranges from 2 to 21 days, which aligns with the statement provided.	"{""explanation"": ""The literature specifies that the incubation period for Ebola virus disease ranges from 2 to 21 days, which aligns with the statement provided."", ""reference"": ""PMID:25763588"", ""snippet"": ""The incubation period of the disease ranges from 2 to 21 days."", ""supports"": ""SUPPORT""}"
2497	2310	101	Ehlers-Danlos Syndrome	Ehlers-Danlos_Syndrome.yaml	progression	0	evidence	0	PMID:32333004	NO_EVIDENCE		Systemic sclerosis is a heterogeneous, multisystem disease. It can occur at any age, but most patients develop the disease between the age of 40 to 50 years.	This study is about systemic sclerosis and does not provide evidence regarding the progression or onset of Ehlers-Danlos Syndrome specifically.	"{""explanation"": ""This study is about systemic sclerosis and does not provide evidence regarding the progression or onset of Ehlers-Danlos Syndrome specifically."", ""reference"": ""PMID:32333004"", ""snippet"": ""Systemic sclerosis is a heterogeneous, multisystem disease. It can occur at any age, but most patients develop the disease between the age of 40 to 50 years."", ""supports"": ""NO_EVIDENCE""}"
2498	2310	101	Ehlers-Danlos Syndrome	Ehlers-Danlos_Syndrome.yaml	progression	0	evidence	1	PMID:21193204	SUPPORT		Patients whose first echocardiogram was obtained in late childhood or adulthood were less likely to have aortic dilation (P < .002) than those whose first echocardiogram was obtained in early childhood.	This study suggests that certain clinical findings related to EDS, such as aortic dilation, are more pronounced in childhood, supporting earlier onset and progression.	"{""explanation"": ""This study suggests that certain clinical findings related to EDS, such as aortic dilation, are more pronounced in childhood, supporting earlier onset and progression."", ""reference"": ""PMID:21193204"", ""snippet"": ""Patients whose first echocardiogram was obtained in late childhood or adulthood were less likely to have aortic dilation (P < .002) than those whose first echocardiogram was obtained in early childhood."", ""supports"": ""SUPPORT""}"
2499	2310	101	Ehlers-Danlos Syndrome	Ehlers-Danlos_Syndrome.yaml	progression	0	evidence	2	PMID:24499752	SUPPORT		There is a much greater prevalence of obstetric and gynecologic issues reported by women with Ehlers-Danlos syndrome than in the general population. Additionally, rates differed significantly among the three most common types of Ehlers-Danlos syndrome with vascular type having the highest rates of adverse pregnancy outcomes and menstrual abnormalities.	The study discusses the prevalence of gynecologic and obstetric issues in women with Ehlers-Danlos Syndrome, implying that some symptoms and complications start or can be observed from an early age.	"{""explanation"": ""The study discusses the prevalence of gynecologic and obstetric issues in women with Ehlers-Danlos Syndrome, implying that some symptoms and complications start or can be observed from an early age."", ""reference"": ""PMID:24499752"", ""snippet"": ""There is a much greater prevalence of obstetric and gynecologic issues reported by women with Ehlers-Danlos syndrome than in the general population. Additionally, rates differed significantly among the three most common types of Ehlers-Danlos syndrome with vascular type having the highest rates of adverse pregnancy outcomes and menstrual abnormalities."", ""supports"": ""SUPPORT""}"
2500	2310	101	Ehlers-Danlos Syndrome	Ehlers-Danlos_Syndrome.yaml	progression	0	evidence	3	PMID:29982180	SUPPORT		Arterial fragility is an important characteristic of kyphoscoliotic EDS. It manifests as spontaneous arterial rupture, dissections and dissecting aneurysms which may occur even during early childhood.	This study highlights that arterial fragility in kyphoscoliotic EDS can manifest as early as childhood, supporting the statement regarding early onset and progression of the disease.	"{""explanation"": ""This study highlights that arterial fragility in kyphoscoliotic EDS can manifest as early as childhood, supporting the statement regarding early onset and progression of the disease."", ""reference"": ""PMID:29982180"", ""snippet"": ""Arterial fragility is an important characteristic of kyphoscoliotic EDS. It manifests as spontaneous arterial rupture, dissections and dissecting aneurysms which may occur even during early childhood."", ""supports"": ""SUPPORT""}"
2501	2311	101	Ehlers-Danlos Syndrome	Ehlers-Danlos_Syndrome.yaml	progression	1	evidence	0	PMID:37261967	REFUTE		OBJECTIVE: This review sought to identify studies regarding aging in hEDS/HSD... No study had a stated aim regarding aging in hEDS/HSD, but all studies corroborated earlier natural history studies describing the age-related trajectory of manifestations in younger people. Studies found that symptom progression was heterogeneous, multisystemic, and unpredictable.	The statement that there is a common age range where symptoms peak is refuted by the literature's indication that symptom progression is heterogeneous, multisystemic, and unpredictable.	"{""explanation"": ""The statement that there is a common age range where symptoms peak is refuted by the literature's indication that symptom progression is heterogeneous, multisystemic, and unpredictable."", ""reference"": ""PMID:37261967"", ""snippet"": ""OBJECTIVE: This review sought to identify studies regarding aging in hEDS/HSD... No study had a stated aim regarding aging in hEDS/HSD, but all studies corroborated earlier natural history studies describing the age-related trajectory of manifestations in younger people. Studies found that symptom progression was heterogeneous, multisystemic, and unpredictable."", ""supports"": ""REFUTE""}"
2553	2334	102	Ehlers-Danlos Syndrome, COL5A1-related	Ehlers-Danlos_Syndrome_COL5A1-related.yaml	progression	0	evidence	0	PMID:20847697	PARTIAL		Classic Ehlers-Danlos syndrome is a heritable connective tissue disorder characterized by skin hyperextensibility, fragile and soft skin, delayed wound healing with formation of atrophic scars, easy bruising, and generalized joint hypermobility.	While the COL5A1-related Ehlers-Danlos Syndrome (classic type) is described as a heritable connective tissue disorder with certain clinical features observable from birth, the literature does not specifically detail the age range for the onset of symptoms as 'Birth-20'.	"{""explanation"": ""While the COL5A1-related Ehlers-Danlos Syndrome (classic type) is described as a heritable connective tissue disorder with certain clinical features observable from birth, the literature does not specifically detail the age range for the onset of symptoms as 'Birth-20'."", ""reference"": ""PMID:20847697"", ""snippet"": ""Classic Ehlers-Danlos syndrome is a heritable connective tissue disorder characterized by skin hyperextensibility, fragile and soft skin, delayed wound healing with formation of atrophic scars, easy bruising, and generalized joint hypermobility."", ""supports"": ""PARTIAL""}"
2755	2637	115	Familial Mediterranean Fever	Familial_Mediterranean_Fever.yaml	progression	0	evidence	0	PMID:31999206	SUPPORT		Of 1687 patients, 761 had first FMF attack at </=3 years of age while 926 patients presented with their first manifestation of FMF at >3 years.	The study provides evidence that FMF onset can occur in childhood.	"{""explanation"": ""The study provides evidence that FMF onset can occur in childhood."", ""reference"": ""PMID:31999206"", ""snippet"": ""Of 1687 patients, 761 had first FMF attack at </=3 years of age while 926 patients presented with their first manifestation of FMF at >3 years."", ""supports"": ""SUPPORT""}"
2756	2637	115	Familial Mediterranean Fever	Familial_Mediterranean_Fever.yaml	progression	0	evidence	1	PMID:23194659	SUPPORT		Median age at first symptoms was 4 years (range 3 month-37 years) and at diagnosis 10 years (range 2-44 years).	This reference supports the statement by indicating that the majority of FMF cases have an onset in childhood.	"{""explanation"": ""This reference supports the statement by indicating that the majority of FMF cases have an onset in childhood."", ""reference"": ""PMID:23194659"", ""snippet"": ""Median age at first symptoms was 4 years (range 3 month-37 years) and at diagnosis 10 years (range 2-44 years)."", ""supports"": ""SUPPORT""}"
3596	3605	151	Hepatitis B	Hepatitis_B.yaml	progression	0	evidence	0	PMID:270889	SUPPORT		Fatigue started median 4 weeks, abdominal symptoms median 3 weeks and signs of cholestasis median 2.5 weeks before peak SGPT values were reached.	The study indicates that symptoms of acute hepatitis B, including fatigue and abdominal symptoms, manifest over a period of weeks, supporting the statement.	"{""explanation"": ""The study indicates that symptoms of acute hepatitis B, including fatigue and abdominal symptoms, manifest over a period of weeks, supporting the statement."", ""reference"": ""PMID:270889"", ""snippet"": ""Fatigue started median 4 weeks, abdominal symptoms median 3 weeks and signs of cholestasis median 2.5 weeks before peak SGPT values were reached."", ""supports"": ""SUPPORT""}"
3597	3605	151	Hepatitis B	Hepatitis_B.yaml	progression	0	evidence	1	PMID:3967850	SUPPORT		The median follow-up time was 8 months (range, 1 week to 3 years). HBV DNA was detected in 26 (34%) patients on admission to the hospital.	This reference suggests that acute hepatitis B can have a duration ranging from weeks to several months, aligning with the statement.	"{""explanation"": ""This reference suggests that acute hepatitis B can have a duration ranging from weeks to several months, aligning with the statement."", ""reference"": ""PMID:3967850"", ""snippet"": ""The median follow-up time was 8 months (range, 1 week to 3 years). HBV DNA was detected in 26 (34%) patients on admission to the hospital."", ""supports"": ""SUPPORT""}"
3598	3606	151	Hepatitis B	Hepatitis_B.yaml	progression	1	evidence	0	PMID:18067957	SUPPORT		The knowledge of the HBV organization and replication cycle and the availability of sensitive HBV-DNA assays have led to remarkable progress in our understanding of the natural history of chronic hepatitis B infections.	The reference discusses the natural history of chronic hepatitis B infections, implying a prolonged duration.	"{""explanation"": ""The reference discusses the natural history of chronic hepatitis B infections, implying a prolonged duration."", ""reference"": ""PMID:18067957"", ""snippet"": ""The knowledge of the HBV organization and replication cycle and the availability of sensitive HBV-DNA assays have led to remarkable progress in our understanding of the natural history of chronic hepatitis B infections."", ""supports"": ""SUPPORT""}"
3599	3606	151	Hepatitis B	Hepatitis_B.yaml	progression	1	evidence	1	PMID:28468285	SUPPORT		Chronic infection with hepatitis B virus (HBV) progresses through multiple phases, including immune tolerant, immune active, immune control, and, in a subset of patients who achieve immune control, reactivation.	The reference outlines the prolonged nature of chronic HBV infection, which can last for years to decades through various phases.	"{""explanation"": ""The reference outlines the prolonged nature of chronic HBV infection, which can last for years to decades through various phases."", ""reference"": ""PMID:28468285"", ""snippet"": ""Chronic infection with hepatitis B virus (HBV) progresses through multiple phases, including immune tolerant, immune active, immune control, and, in a subset of patients who achieve immune control, reactivation."", ""supports"": ""SUPPORT""}"
3600	3606	151	Hepatitis B	Hepatitis_B.yaml	progression	1	evidence	2	PMID:21205148	SUPPORT		Chronic hepatitis B virus (HBV) infection is a dynamic series of interactions between HBV, hepatocytes and the patient's immune system. HBV replication is the key motor of disease progression, including the development of cirrhosis and hepatocellular carcinoma (HCC).	The reference indicates the long-term nature of chronic HBV infection and its potential to lead to serious liver conditions over time.	"{""explanation"": ""The reference indicates the long-term nature of chronic HBV infection and its potential to lead to serious liver conditions over time."", ""reference"": ""PMID:21205148"", ""snippet"": ""Chronic hepatitis B virus (HBV) infection is a dynamic series of interactions between HBV, hepatocytes and the patient's immune system. HBV replication is the key motor of disease progression, including the development of cirrhosis and hepatocellular carcinoma (HCC)."", ""supports"": ""SUPPORT""}"
3601	3606	151	Hepatitis B	Hepatitis_B.yaml	progression	1	evidence	3	PMID:12616451	SUPPORT		Many HBV-infected children have normal alanine aminotransferase values and minimal chronic hepatitis. Children with chronic HBV infection are usually asymptomatic but may develop chronic liver disease or hepatocellular carcinoma.	The reference highlights that chronic HBV infection can last for a long duration, potentially leading to serious liver conditions.	"{""explanation"": ""The reference highlights that chronic HBV infection can last for a long duration, potentially leading to serious liver conditions."", ""reference"": ""PMID:12616451"", ""snippet"": ""Many HBV-infected children have normal alanine aminotransferase values and minimal chronic hepatitis. Children with chronic HBV infection are usually asymptomatic but may develop chronic liver disease or hepatocellular carcinoma."", ""supports"": ""SUPPORT""}"
3602	3606	151	Hepatitis B	Hepatitis_B.yaml	progression	1	evidence	4	PMID:6994954	SUPPORT		Fewer than 10% of cases of acute icteric HBV become chronic, but chronicity is more common after anicteric infections. The prognosis for chronic persistent hepatitis B is usually good whereas many cases of chronic active hepatitis B will progress to cirrhosis although the time scale may be long.	The reference supports the statement by indicating that chronic HBV infection can last for years to decades, with potential progression to cirrhosis.	"{""explanation"": ""The reference supports the statement by indicating that chronic HBV infection can last for years to decades, with potential progression to cirrhosis."", ""reference"": ""PMID:6994954"", ""snippet"": ""Fewer than 10% of cases of acute icteric HBV become chronic, but chronicity is more common after anicteric infections. The prognosis for chronic persistent hepatitis B is usually good whereas many cases of chronic active hepatitis B will progress to cirrhosis although the time scale may be long."", ""supports"": ""SUPPORT""}"
3603	3607	151	Hepatitis B	Hepatitis_B.yaml	progression	2	evidence	0	PMID:18067957	SUPPORT		The knowledge of the HBV organization and replication cycle and the availability of sensitive HBV-DNA assays have led to remarkable progress in our understanding of the natural history of chronic hepatitis B infections.	The statement is supported as it mentions the natural history of chronic hepatitis B infections, which implies variability in the duration of the infection.	"{""explanation"": ""The statement is supported as it mentions the natural history of chronic hepatitis B infections, which implies variability in the duration of the infection."", ""reference"": ""PMID:18067957"", ""snippet"": ""The knowledge of the HBV organization and replication cycle and the availability of sensitive HBV-DNA assays have led to remarkable progress in our understanding of the natural history of chronic hepatitis B infections."", ""supports"": ""SUPPORT""}"
3604	3607	151	Hepatitis B	Hepatitis_B.yaml	progression	2	evidence	1	PMID:33545773	SUPPORT		Patients with chronic HBV infection and an excessive drinking habit activate HBV-DNA which increases liver inflammation, thus accelerating the progress of liver cirrhosis.	This reference supports the statement as it discusses the progression of chronic HBV infection to liver cirrhosis, indicating a variable duration of the disease progression depending on external factors like alcohol intake.	"{""explanation"": ""This reference supports the statement as it discusses the progression of chronic HBV infection to liver cirrhosis, indicating a variable duration of the disease progression depending on external factors like alcohol intake."", ""reference"": ""PMID:33545773"", ""snippet"": ""Patients with chronic HBV infection and an excessive drinking habit activate HBV-DNA which increases liver inflammation, thus accelerating the progress of liver cirrhosis."", ""supports"": ""SUPPORT""}"
3605	3607	151	Hepatitis B	Hepatitis_B.yaml	progression	2	evidence	2	PMID:33029534	SUPPORT		Liver-function decompensation or hepatocellular carcinoma (HCC) gradually appears after chronic hepatitis B progresses to cirrhosis.	The reference supports the statement by indicating that chronic hepatitis B can progress to cirrhosis, which aligns with the note about chronic infection causing liver scarring and dysfunction.	"{""explanation"": ""The reference supports the statement by indicating that chronic hepatitis B can progress to cirrhosis, which aligns with the note about chronic infection causing liver scarring and dysfunction."", ""reference"": ""PMID:33029534"", ""snippet"": ""Liver-function decompensation or hepatocellular carcinoma (HCC) gradually appears after chronic hepatitis B progresses to cirrhosis."", ""supports"": ""SUPPORT""}"
3606	3607	151	Hepatitis B	Hepatitis_B.yaml	progression	2	evidence	3	PMID:32147592	SUPPORT		In a longitudinal study of patients with chronic HBV infection, we associated liver fibrosis progression at week 78 of treatment with higher rates of detected HBV DNA.	This reference supports the statement by discussing the progression of fibrosis in chronic HBV infection, indicating variability in disease duration.	"{""explanation"": ""This reference supports the statement by discussing the progression of fibrosis in chronic HBV infection, indicating variability in disease duration."", ""reference"": ""PMID:32147592"", ""snippet"": ""In a longitudinal study of patients with chronic HBV infection, we associated liver fibrosis progression at week 78 of treatment with higher rates of detected HBV DNA."", ""supports"": ""SUPPORT""}"
3607	3607	151	Hepatitis B	Hepatitis_B.yaml	progression	2	evidence	4	PMID:25253946	SUPPORT		The histological end points of CAH are chronic inflammation, fibrosis and cirrhosis which are coupled with increased DNA synthesis in cirrhotic vs healthy normal livers.	The reference supports the statement by describing the progression of chronic active hepatitis (CAH) to cirrhosis, indicating variability in the duration of disease progression.	"{""explanation"": ""The reference supports the statement by describing the progression of chronic active hepatitis (CAH) to cirrhosis, indicating variability in the duration of disease progression."", ""reference"": ""PMID:25253946"", ""snippet"": ""The histological end points of CAH are chronic inflammation, fibrosis and cirrhosis which are coupled with increased DNA synthesis in cirrhotic vs healthy normal livers."", ""supports"": ""SUPPORT""}"
3608	3608	151	Hepatitis B	Hepatitis_B.yaml	progression	3	evidence	0	PMID:20378277	SUPPORT		Chronic HBV infection is the most prevalent cause of this tumour, accounting for 55% of global cases, and 89% of those in endemic regions for HBV infection.	The literature clearly states that chronic HBV infection significantly increases the risk of hepatocellular carcinoma (HCC).	"{""explanation"": ""The literature clearly states that chronic HBV infection significantly increases the risk of hepatocellular carcinoma (HCC)."", ""reference"": ""PMID:20378277"", ""snippet"": ""Chronic HBV infection is the most prevalent cause of this tumour, accounting for 55% of global cases, and 89% of those in endemic regions for HBV infection."", ""supports"": ""SUPPORT""}"
3609	3608	151	Hepatitis B	Hepatitis_B.yaml	progression	3	evidence	1	PMID:31450890	SUPPORT		Our study revealed that HBsAg levels >/= 100 IU/ml, and notably >1,000 IU/ ml, are associated with an increased risk of HCC development.	The study shows that higher levels of hepatitis B surface antigen, which is indicative of chronic HBV infection, are associated with an increased risk of liver cancer.	"{""explanation"": ""The study shows that higher levels of hepatitis B surface antigen, which is indicative of chronic HBV infection, are associated with an increased risk of liver cancer."", ""reference"": ""PMID:31450890"", ""snippet"": ""Our study revealed that HBsAg levels >/= 100 IU/ml, and notably >1,000 IU/ ml, are associated with an increased risk of HCC development."", ""supports"": ""SUPPORT""}"
3610	3608	151	Hepatitis B	Hepatitis_B.yaml	progression	3	evidence	2	PMID:19399792	SUPPORT		The primary adverse outcomes of chronic HBV infection are hepatocellular carcinoma (HCC) and cirrhosis.	This reference confirms that chronic HBV infection significantly increases the risk of developing hepatocellular carcinoma.	"{""explanation"": ""This reference confirms that chronic HBV infection significantly increases the risk of developing hepatocellular carcinoma."", ""reference"": ""PMID:19399792"", ""snippet"": ""The primary adverse outcomes of chronic HBV infection are hepatocellular carcinoma (HCC) and cirrhosis."", ""supports"": ""SUPPORT""}"
3611	3608	151	Hepatitis B	Hepatitis_B.yaml	progression	3	evidence	3	PMID:32931613	SUPPORT		Hepatitis B virus (HBV) is a major cause of chronic liver disease, which can progress to cirrhosis, hepatocellular carcinoma, and death.	The literature indicates that chronic HBV infection can lead to hepatocellular carcinoma, supporting the statement.	"{""explanation"": ""The literature indicates that chronic HBV infection can lead to hepatocellular carcinoma, supporting the statement."", ""reference"": ""PMID:32931613"", ""snippet"": ""Hepatitis B virus (HBV) is a major cause of chronic liver disease, which can progress to cirrhosis, hepatocellular carcinoma, and death."", ""supports"": ""SUPPORT""}"
3730	3735	156	Hirschsprung Disease	Hirschsprung_Disease.yaml	progression	0	evidence	0	PMID:2039180	SUPPORT		Hirschsprung disease has become a neonatal diagnosis. Most cases identified now are children who would previously have died before the diagnosis of their condition which was usually established only after the age of two.	The literature states that Hirschsprung's disease is typically diagnosed during the neonatal phase, supporting the statement.	"{""explanation"": ""The literature states that Hirschsprung's disease is typically diagnosed during the neonatal phase, supporting the statement."", ""reference"": ""PMID:2039180"", ""snippet"": ""Hirschsprung disease has become a neonatal diagnosis. Most cases identified now are children who would previously have died before the diagnosis of their condition which was usually established only after the age of two."", ""supports"": ""SUPPORT""}"
3731	3735	156	Hirschsprung Disease	Hirschsprung_Disease.yaml	progression	0	evidence	1	PMID:4060039	SUPPORT		This review of Hirschsprung's disease reflects the authors' experience with it and outlines the current recommendations for management of its various manifestations.	While the abstract does not explicitly specify the neonatal phase, it mentions current management practices and experiences, implying early diagnosis and treatment.	"{""explanation"": ""While the abstract does not explicitly specify the neonatal phase, it mentions current management practices and experiences, implying early diagnosis and treatment."", ""reference"": ""PMID:4060039"", ""snippet"": ""This review of Hirschsprung's disease reflects the authors' experience with it and outlines the current recommendations for management of its various manifestations."", ""supports"": ""SUPPORT""}"
3732	3735	156	Hirschsprung Disease	Hirschsprung_Disease.yaml	progression	0	evidence	2	PMID:25066220	SUPPORT		Hirschsprung's disease is a congenital gut motility disorder, characterised by the absence of the enteric ganglion cells along the distal gut.	Although this does not explicitly state the neonatal onset, congenital disorders are typically identified at birth or soon after, thus supporting the statement indirectly.	"{""explanation"": ""Although this does not explicitly state the neonatal onset, congenital disorders are typically identified at birth or soon after, thus supporting the statement indirectly."", ""reference"": ""PMID:25066220"", ""snippet"": ""Hirschsprung's disease is a congenital gut motility disorder, characterised by the absence of the enteric ganglion cells along the distal gut."", ""supports"": ""SUPPORT""}"
3944	3837	160	Hypertensive Heart Disease	Hypertensive_Heart_Disease.yaml	progression	0	evidence	0	PMID:38596912	SUPPORT		This study documents the point prevalence of subclinical heart disease in emergency patients with asymptomatic hypertension.	This reference supports the statement for the asymptomatic phase by documenting the presence of subclinical heart disease in patients with asymptomatic hypertension, which aligns with the concept of progression in hypertensive heart disease, but it does not focus specifically on the age range of 40-60.	"{""explanation"": ""This reference supports the statement for the asymptomatic phase by documenting the presence of subclinical heart disease in patients with asymptomatic hypertension, which aligns with the concept of progression in hypertensive heart disease, but it does not focus specifically on the age range of 40-60."", ""reference"": ""PMID:38596912"", ""snippet"": ""This study documents the point prevalence of subclinical heart disease in emergency patients with asymptomatic hypertension."", ""supports"": ""SUPPORT""}"
3945	3838	160	Hypertensive Heart Disease	Hypertensive_Heart_Disease.yaml	progression	1	evidence	0	PMID:21263005	PARTIAL		The progression of hypertensive heart disease.	The reference discusses the progression of hypertensive heart disease but does not specify the age range of 50-80 or the phase as symptomatic.	"{""explanation"": ""The reference discusses the progression of hypertensive heart disease but does not specify the age range of 50-80 or the phase as symptomatic."", ""reference"": ""PMID:21263005"", ""snippet"": ""The progression of hypertensive heart disease."", ""supports"": ""PARTIAL""}"
3946	3838	160	Hypertensive Heart Disease	Hypertensive_Heart_Disease.yaml	progression	1	evidence	1	PMID:38596912	NO_EVIDENCE		Black, Hispanic, and female patients with asymptomatic hypertension are on the continuum for developing overt heart failure.	The study focuses on the prevalence of subclinical heart disease in asymptomatic hypertensive patients, without specifying the age range of 50-80 or mentioning symptomatic progression.	"{""explanation"": ""The study focuses on the prevalence of subclinical heart disease in asymptomatic hypertensive patients, without specifying the age range of 50-80 or mentioning symptomatic progression."", ""reference"": ""PMID:38596912"", ""snippet"": ""Black, Hispanic, and female patients with asymptomatic hypertension are on the continuum for developing overt heart failure."", ""supports"": ""NO_EVIDENCE""}"
3947	3838	160	Hypertensive Heart Disease	Hypertensive_Heart_Disease.yaml	progression	1	evidence	2	PMID:37698022	PARTIAL		In the past three decades, there has been an overall increasing trend in the prevalence of HHD among older adults worldwide.	While the reference provides data about the prevalence and burden of hypertensive heart disease among older adults, it does not specifically address the symptomatic progression of the disease.	"{""explanation"": ""While the reference provides data about the prevalence and burden of hypertensive heart disease among older adults, it does not specifically address the symptomatic progression of the disease."", ""reference"": ""PMID:37698022"", ""snippet"": ""In the past three decades, there has been an overall increasing trend in the prevalence of HHD among older adults worldwide."", ""supports"": ""PARTIAL""}"
3948	3838	160	Hypertensive Heart Disease	Hypertensive_Heart_Disease.yaml	progression	1	evidence	3	PMID:34809918	SUPPORT		Pulmonary hypertension (PH) due to left heart disease (LHD; group 2 PH) is a common complication of heart failure.	The reference describes pulmonary hypertension due to left heart disease as a progression related to heart failure, which fits the description of symptomatic progression within the age range.	"{""explanation"": ""The reference describes pulmonary hypertension due to left heart disease as a progression related to heart failure, which fits the description of symptomatic progression within the age range."", ""reference"": ""PMID:34809918"", ""snippet"": ""Pulmonary hypertension (PH) due to left heart disease (LHD; group 2 PH) is a common complication of heart failure."", ""supports"": ""SUPPORT""}"
3949	3838	160	Hypertensive Heart Disease	Hypertensive_Heart_Disease.yaml	progression	1	evidence	4	PMID:35138872	NO_EVIDENCE		The presence of HMOD confers incremental prognostic information regarding cardiovascular disease risk at every BP category.	The study emphasizes the presence and prognosis of hypertension-mediated organ damage but does not detail the progression of hypertensive heart disease specifically within the 50-80 age range or the symptomatic phase.	"{""explanation"": ""The study emphasizes the presence and prognosis of hypertension-mediated organ damage but does not detail the progression of hypertensive heart disease specifically within the 50-80 age range or the symptomatic phase."", ""reference"": ""PMID:35138872"", ""snippet"": ""The presence of HMOD confers incremental prognostic information regarding cardiovascular disease risk at every BP category."", ""supports"": ""NO_EVIDENCE""}"
4035	3876	161	Hypertrophic Cardiomyopathy	Hypertrophic_Cardiomyopathy.yaml	progression	0	evidence	0	PMID:25897040	SUPPORT		Myocardial fibrosis in HCM is a progressive phenomenon. Non-apical phenotype and a higher LGE extent at CMR-1 are both associated with greater LGE progression.	The literature supports that hypertrophic cardiomyopathy (HCM) can progress over time, which implies progression from an initial onset phase.	"{""explanation"": ""The literature supports that hypertrophic cardiomyopathy (HCM) can progress over time, which implies progression from an initial onset phase."", ""reference"": ""PMID:25897040"", ""snippet"": ""Myocardial fibrosis in HCM is a progressive phenomenon. Non-apical phenotype and a higher LGE extent at CMR-1 are both associated with greater LGE progression."", ""supports"": ""SUPPORT""}"
4036	3876	161	Hypertrophic Cardiomyopathy	Hypertrophic_Cardiomyopathy.yaml	progression	0	evidence	1	PMID:22158452	SUPPORT		Progressive heart failure associated with left ventricular remodeling and systo-diastolic dysfunction is one of the most severe complications of hypertrophic cardiomyopathy (HCM).	The progression of hypertrophic cardiomyopathy (HCM) through various stages, including an onset phase, is indicated by the reference to progressive heart failure.	"{""explanation"": ""The progression of hypertrophic cardiomyopathy (HCM) through various stages, including an onset phase, is indicated by the reference to progressive heart failure."", ""reference"": ""PMID:22158452"", ""snippet"": ""Progressive heart failure associated with left ventricular remodeling and systo-diastolic dysfunction is one of the most severe complications of hypertrophic cardiomyopathy (HCM)."", ""supports"": ""SUPPORT""}"
4037	3876	161	Hypertrophic Cardiomyopathy	Hypertrophic_Cardiomyopathy.yaml	progression	0	evidence	2	PMID:29111210	SUPPORT		Hypertrophic cardiomyopathy (HC) has been characterized as a generally progressive genetic heart disease...	The statement that HC is generally progressive suggests that there is an initial onset phase followed by further disease progression.	"{""explanation"": ""The statement that HC is generally progressive suggests that there is an initial onset phase followed by further disease progression."", ""reference"": ""PMID:29111210"", ""snippet"": ""Hypertrophic cardiomyopathy (HC) has been characterized as a generally progressive genetic heart disease..."", ""supports"": ""SUPPORT""}"
4038	3877	161	Hypertrophic Cardiomyopathy	Hypertrophic_Cardiomyopathy.yaml	progression	1	evidence	0	PMID:29622585	SUPPORT		In the subset of patients with serial imaging, statistically significant increases in LGE, LV mass, and left atrial size were detected over 2.5 years, indicating disease progression over time.	This study shows significant disease progression, including increases in late gadolinium enhancement (LGE), left ventricular (LV) mass, and left atrial size, indicating that hypertrophic cardiomyopathy progresses over time from adolescence into adulthood.	"{""explanation"": ""This study shows significant disease progression, including increases in late gadolinium enhancement (LGE), left ventricular (LV) mass, and left atrial size, indicating that hypertrophic cardiomyopathy progresses over time from adolescence into adulthood."", ""reference"": ""PMID:29622585"", ""snippet"": ""In the subset of patients with serial imaging, statistically significant increases in LGE, LV mass, and left atrial size were detected over 2.5 years, indicating disease progression over time."", ""supports"": ""SUPPORT""}"
4039	3877	161	Hypertrophic Cardiomyopathy	Hypertrophic_Cardiomyopathy.yaml	progression	1	evidence	1	PMID:29710196	SUPPORT		Pediatric-onset HCM is rare and associated with adverse outcomes driven mainly by arrhythmic events. Risk extends well beyond adolescence, which calls for unchanged clinical surveillance into adulthood.	This study highlights that pediatric-onset HCM progresses into adulthood and is associated with adverse outcomes, supporting continuous clinical surveillance.	"{""explanation"": ""This study highlights that pediatric-onset HCM progresses into adulthood and is associated with adverse outcomes, supporting continuous clinical surveillance."", ""reference"": ""PMID:29710196"", ""snippet"": ""Pediatric-onset HCM is rare and associated with adverse outcomes driven mainly by arrhythmic events. Risk extends well beyond adolescence, which calls for unchanged clinical surveillance into adulthood."", ""supports"": ""SUPPORT""}"
4170	4100	173	Jeavons Syndrome	Jeavons_Syndrome.yaml	progression	0	evidence	0	PMID:32554361	SUPPORT		The mean age at seizure onset was 8.7+/-5.3 years and the mean age at admission to hospital was 17.8+/-10.7 years.	This study provides data supporting the age range for seizure onset in Jeavons Syndrome patients, with a mean age of onset fitting within the range of 2 to 14 years.	"{""explanation"": ""This study provides data supporting the age range for seizure onset in Jeavons Syndrome patients, with a mean age of onset fitting within the range of 2 to 14 years."", ""reference"": ""PMID:32554361"", ""snippet"": ""The mean age at seizure onset was 8.7+/-5.3 years and the mean age at admission to hospital was 17.8+/-10.7 years."", ""supports"": ""SUPPORT""}"
4251	4210	177	Kawasaki Disease	Kawasaki_Disease.yaml	progression	0	evidence	0	PMID:36472296	PARTIAL		Given the variety and inconsistency of the clinical symptoms (the child had four of the five mandatory criteria together with prolonged fever), there was a late diagnosis, namely on day 10 of the disease.	This reference mentions prolonged fever as a symptom of Kawasaki Disease but does not specify the sudden onset of high fever.	"{""explanation"": ""This reference mentions prolonged fever as a symptom of Kawasaki Disease but does not specify the sudden onset of high fever."", ""reference"": ""PMID:36472296"", ""snippet"": ""Given the variety and inconsistency of the clinical symptoms (the child had four of the five mandatory criteria together with prolonged fever), there was a late diagnosis, namely on day 10 of the disease."", ""supports"": ""PARTIAL""}"
4252	4210	177	Kawasaki Disease	Kawasaki_Disease.yaml	progression	0	evidence	1	PMID:34459958	PARTIAL		A retrospective study that compared children younger than 6 months versus older children of a Spanish cohort of patients diagnosed with Kawasaki disease between 2011 and 2016 (Kawa-Race study).	This reference provides information on Kawasaki Disease in children younger than 6 months and older but does not specifically mention the age range of 6 months to 5 years or the sudden onset with high fever.	"{""explanation"": ""This reference provides information on Kawasaki Disease in children younger than 6 months and older but does not specifically mention the age range of 6 months to 5 years or the sudden onset with high fever."", ""reference"": ""PMID:34459958"", ""snippet"": ""A retrospective study that compared children younger than 6 months versus older children of a Spanish cohort of patients diagnosed with Kawasaki disease between 2011 and 2016 (Kawa-Race study)."", ""supports"": ""PARTIAL""}"
4253	4210	177	Kawasaki Disease	Kawasaki_Disease.yaml	progression	0	evidence	2	PMID:37553209	PARTIAL		The mean age was 39.8 months (SD 37) and 592 (59%) were boys.	This reference indicates that the mean age of Kawasaki Disease patients was within the 6 months to 5 years range but does not specifically mention the sudden onset with high fever.	"{""explanation"": ""This reference indicates that the mean age of Kawasaki Disease patients was within the 6 months to 5 years range but does not specifically mention the sudden onset with high fever."", ""reference"": ""PMID:37553209"", ""snippet"": ""The mean age was 39.8 months (SD 37) and 592 (59%) were boys."", ""supports"": ""PARTIAL""}"
4254	4210	177	Kawasaki Disease	Kawasaki_Disease.yaml	progression	0	evidence	3	PMID:31910632	PARTIAL		Kawasaki disease (KD) is the most frequent cause of coronary artery aneurysm (CAA) in children.	This reference focuses on coronary artery aneurysm in children with Kawasaki Disease but does not provide specific details about the age range or the sudden onset with high fever.	"{""explanation"": ""This reference focuses on coronary artery aneurysm in children with Kawasaki Disease but does not provide specific details about the age range or the sudden onset with high fever."", ""reference"": ""PMID:31910632"", ""snippet"": ""Kawasaki disease (KD) is the most frequent cause of coronary artery aneurysm (CAA) in children."", ""supports"": ""PARTIAL""}"
4255	4210	177	Kawasaki Disease	Kawasaki_Disease.yaml	progression	0	evidence	4	PMID:36611091	PARTIAL		83% of patients were < 5 years of age and 10% were < 6 months.	This reference mentions that 83% of Kawasaki Disease patients were under 5 years of age but does not specify the sudden onset with high fever.	"{""explanation"": ""This reference mentions that 83% of Kawasaki Disease patients were under 5 years of age but does not specify the sudden onset with high fever."", ""reference"": ""PMID:36611091"", ""snippet"": ""83% of patients were < 5 years of age and 10% were < 6 months."", ""supports"": ""PARTIAL""}"
4256	4211	177	Kawasaki Disease	Kawasaki_Disease.yaml	progression	1	evidence	0	PMID:9665974	PARTIAL		The illness is manifested by prolonged fever, conjunctival injection, enanthem, exanthem, erythema and swelling of the hands and feet, and cervical adenopathy. These acute features of illness are self-limiting.	The reference confirms the symptoms mentioned in the statement (high fever, rash, conjunctivitis, swollen hands and feet) during the acute phase of Kawasaki Disease. However, it does not specify the exact duration of 1-2 weeks.	"{""explanation"": ""The reference confirms the symptoms mentioned in the statement (high fever, rash, conjunctivitis, swollen hands and feet) during the acute phase of Kawasaki Disease. However, it does not specify the exact duration of 1-2 weeks."", ""reference"": ""PMID:9665974"", ""snippet"": ""The illness is manifested by prolonged fever, conjunctival injection, enanthem, exanthem, erythema and swelling of the hands and feet, and cervical adenopathy. These acute features of illness are self-limiting."", ""supports"": ""PARTIAL""}"
4257	4211	177	Kawasaki Disease	Kawasaki_Disease.yaml	progression	1	evidence	1	PMID:31974671	PARTIAL		Arthritis in KD is usually non-erosive, self-limiting, and responds well to a short course of NSAIDs.	The reference mentions that arthritis in KD is self-limiting, which implies a limited duration. However, it does not explicitly confirm the 1-2 week duration for the acute phase.	"{""explanation"": ""The reference mentions that arthritis in KD is self-limiting, which implies a limited duration. However, it does not explicitly confirm the 1-2 week duration for the acute phase."", ""reference"": ""PMID:31974671"", ""snippet"": ""Arthritis in KD is usually non-erosive, self-limiting, and responds well to a short course of NSAIDs."", ""supports"": ""PARTIAL""}"
4258	4211	177	Kawasaki Disease	Kawasaki_Disease.yaml	progression	1	evidence	2	PMID:39117827	PARTIAL		Kawasaki disease (KD) is a hyperinflammatory syndrome manifesting as an acute systemic vasculitis characterized by fever, nonsuppurative conjunctival injection, rash, oral mucositis, extremity changes, and cervical lymphadenopathy.	The reference confirms the symptoms mentioned in the statement during the acute phase of Kawasaki Disease. However, it does not specify the exact duration of 1-2 weeks.	"{""explanation"": ""The reference confirms the symptoms mentioned in the statement during the acute phase of Kawasaki Disease. However, it does not specify the exact duration of 1-2 weeks."", ""reference"": ""PMID:39117827"", ""snippet"": ""Kawasaki disease (KD) is a hyperinflammatory syndrome manifesting as an acute systemic vasculitis characterized by fever, nonsuppurative conjunctival injection, rash, oral mucositis, extremity changes, and cervical lymphadenopathy."", ""supports"": ""PARTIAL""}"
4259	4212	177	Kawasaki Disease	Kawasaki_Disease.yaml	progression	2	evidence	0	PMID:28580712	PARTIAL		Kawasaki disease begins as a necrotizing arteritis with neutrophilic infiltrate, followed by subacute/chronic changes and luminal myofibroblastic proliferation that can cause coronary artery stenosis.	This reference mentions the subacute phase and coronary artery changes but does not specify the duration of 2-4 weeks or mention peeling skin and joint pain.	"{""explanation"": ""This reference mentions the subacute phase and coronary artery changes but does not specify the duration of 2-4 weeks or mention peeling skin and joint pain."", ""reference"": ""PMID:28580712"", ""snippet"": ""Kawasaki disease begins as a necrotizing arteritis with neutrophilic infiltrate, followed by subacute/chronic changes and luminal myofibroblastic proliferation that can cause coronary artery stenosis."", ""supports"": ""PARTIAL""}"
4260	4212	177	Kawasaki Disease	Kawasaki_Disease.yaml	progression	2	evidence	1	PMID:33453126	PARTIAL		All children with KD have fever accompanied by clinical signs, with four of the five classic criteria for complete KD being mucocutaneous, thus creating an important role for dermatologists.	This reference discusses skin manifestations, which could include peeling, but does not specify the subacute phase duration or joint pain.	"{""explanation"": ""This reference discusses skin manifestations, which could include peeling, but does not specify the subacute phase duration or joint pain."", ""reference"": ""PMID:33453126"", ""snippet"": ""All children with KD have fever accompanied by clinical signs, with four of the five classic criteria for complete KD being mucocutaneous, thus creating an important role for dermatologists."", ""supports"": ""PARTIAL""}"
4261	4213	177	Kawasaki Disease	Kawasaki_Disease.yaml	progression	3	evidence	0	PMID:28580712	PARTIAL		Kawasaki disease is an acute febrile arteritis of childhood that can result in coronary artery aneurysms if untreated in the first 10 and ideally 7 days of illness. Kawasaki disease begins as a necrotizing arteritis with neutrophilic infiltrate, followed by subacute/chronic changes and luminal myofibroblastic proliferation that can cause coronary artery stenosis.	The literature indicates that Kawasaki disease can lead to coronary artery abnormalities, but it does not specify that the convalescent phase lasts 6-8 weeks. It supports the persistence of coronary artery abnormalities but does not confirm the exact duration of the convalescent phase.	"{""explanation"": ""The literature indicates that Kawasaki disease can lead to coronary artery abnormalities, but it does not specify that the convalescent phase lasts 6-8 weeks. It supports the persistence of coronary artery abnormalities but does not confirm the exact duration of the convalescent phase."", ""reference"": ""PMID:28580712"", ""snippet"": ""Kawasaki disease is an acute febrile arteritis of childhood that can result in coronary artery aneurysms if untreated in the first 10 and ideally 7 days of illness. Kawasaki disease begins as a necrotizing arteritis with neutrophilic infiltrate, followed by subacute/chronic changes and luminal myofibroblastic proliferation that can cause coronary artery stenosis."", ""supports"": ""PARTIAL""}"
4262	4213	177	Kawasaki Disease	Kawasaki_Disease.yaml	progression	3	evidence	1	PMID:17033807	PARTIAL		Conclusively, the most important predictor of CAA in KD is total duration of fever longer than 8 days. Early identification of IVGG non-responders and active therapeutic intervention for fever in KD cases might decrease the incidence of CAA.	This reference discusses the importance of early intervention to prevent coronary artery abnormalities but does not provide specific information about the duration of the convalescent phase.	"{""explanation"": ""This reference discusses the importance of early intervention to prevent coronary artery abnormalities but does not provide specific information about the duration of the convalescent phase."", ""reference"": ""PMID:17033807"", ""snippet"": ""Conclusively, the most important predictor of CAA in KD is total duration of fever longer than 8 days. Early identification of IVGG non-responders and active therapeutic intervention for fever in KD cases might decrease the incidence of CAA."", ""supports"": ""PARTIAL""}"
4263	4213	177	Kawasaki Disease	Kawasaki_Disease.yaml	progression	3	evidence	2	PMID:29437127	NO_EVIDENCE		Kawasaki Disease.	This reference does not provide specific information about the duration of the convalescent phase or the persistence of coronary artery abnormalities.	"{""explanation"": ""This reference does not provide specific information about the duration of the convalescent phase or the persistence of coronary artery abnormalities."", ""reference"": ""PMID:29437127"", ""snippet"": ""Kawasaki Disease."", ""supports"": ""NO_EVIDENCE""}"
4915	4851	204	Marfan Syndrome	Marfan_Syndrome.yaml	progression	0	evidence	0	PMID:28383843	PARTIAL	HUMAN_CLINICAL	The expression of the Marfan syndrome varies from the severe neonatal presentation to the classical manifestations of the child and young adult, but also comprises isolated features.	The reference indicates that Marfan syndrome can manifest from neonatal stages to young adulthood, but it does not explicitly confirm that the onset is limited to childhood-adolescence.	"{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""The reference indicates that Marfan syndrome can manifest from neonatal stages to young adulthood, but it does not explicitly confirm that the onset is limited to childhood-adolescence."", ""reference"": ""PMID:28383843"", ""snippet"": ""The expression of the Marfan syndrome varies from the severe neonatal presentation to the classical manifestations of the child and young adult, but also comprises isolated features."", ""supports"": ""PARTIAL""}"
4916	4851	204	Marfan Syndrome	Marfan_Syndrome.yaml	progression	0	evidence	1	PMID:35420547	PARTIAL	HUMAN_CLINICAL	Distinct from classical Marfan syndrome in phenotype and morbidity, eoMFS can be diagnosed clinically using an objective scoring system encompassing the typical physical features and cardiac disease manifestations.	This reference discusses early onset Marfan syndrome (eoMFS), which can be diagnosed in early childhood. However, it does not specify that the onset is restricted to childhood-adolescence.	"{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""This reference discusses early onset Marfan syndrome (eoMFS), which can be diagnosed in early childhood. However, it does not specify that the onset is restricted to childhood-adolescence."", ""reference"": ""PMID:35420547"", ""snippet"": ""Distinct from classical Marfan syndrome in phenotype and morbidity, eoMFS can be diagnosed clinically using an objective scoring system encompassing the typical physical features and cardiac disease manifestations."", ""supports"": ""PARTIAL""}"
4917	4851	204	Marfan Syndrome	Marfan_Syndrome.yaml	progression	0	evidence	2	PMID:26631233	NO_EVIDENCE	HUMAN_CLINICAL	We found a median age at diagnose of 19.0 years (range: 0.0-74).	This study indicates that the age of diagnosis ranges widely, from infancy to old age, suggesting that onset is not restricted to childhood-adolescence.	"{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""This study indicates that the age of diagnosis ranges widely, from infancy to old age, suggesting that onset is not restricted to childhood-adolescence."", ""reference"": ""PMID:26631233"", ""snippet"": ""We found a median age at diagnose of 19.0 years (range: 0.0-74)."", ""supports"": ""NO_EVIDENCE""}"
4918	4851	204	Marfan Syndrome	Marfan_Syndrome.yaml	progression	0	evidence	3	PMID:38728377	PARTIAL	HUMAN_CLINICAL	MAD was found in children of all ages, increased +0.18 mm/year (95% CI +0.14, +0.22) during a median duration of 5.5 years (IQR 3.1, 7.5 years).	This study indicates that mitral annular disjunction (MAD) associated with Marfan syndrome can be detected in children of all ages, but it does not confirm that the onset of Marfan syndrome itself is restricted to childhood-adolescence.	"{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""This study indicates that mitral annular disjunction (MAD) associated with Marfan syndrome can be detected in children of all ages, but it does not confirm that the onset of Marfan syndrome itself is restricted to childhood-adolescence."", ""reference"": ""PMID:38728377"", ""snippet"": ""MAD was found in children of all ages, increased +0.18 mm/year (95% CI +0.14, +0.22) during a median duration of 5.5 years (IQR 3.1, 7.5 years)."", ""supports"": ""PARTIAL""}"
4956	4865	205	Meckel Diverticulum	Meckel_Diverticulum.yaml	progression	0	evidence	0	PMID:27492813	SUPPORT		Meckel's diverticulum is usually asymptomatic and found incidentally. However, the lifetime risk of complications is 4-40%.	This describes the natural history and complication rates.	"{""explanation"": ""This describes the natural history and complication rates."", ""reference"": ""PMID:27492813"", ""snippet"": ""Meckel's diverticulum is usually asymptomatic and found incidentally. However, the lifetime risk of complications is 4-40%."", ""supports"": ""SUPPORT""}"
4957	4865	205	Meckel Diverticulum	Meckel_Diverticulum.yaml	progression	0	evidence	1	PMID:8506491	SUPPORT		It is generally believed that less than 5% of them become symptomatic, the frequency decreasing with age.	This indicates that most cases remain asymptomatic and complications decrease with age.	"{""explanation"": ""This indicates that most cases remain asymptomatic and complications decrease with age."", ""reference"": ""PMID:8506491"", ""snippet"": ""It is generally believed that less than 5% of them become symptomatic, the frequency decreasing with age."", ""supports"": ""SUPPORT""}"
4958	4865	205	Meckel Diverticulum	Meckel_Diverticulum.yaml	progression	0	evidence	2	PMID:15026601	SUPPORT		Sixty percent of patients come to medical attention before 10 years of age, with the remainder of cases manifesting in adolescence and adulthood.	This documents the age distribution of symptomatic presentations.	"{""explanation"": ""This documents the age distribution of symptomatic presentations."", ""reference"": ""PMID:15026601"", ""snippet"": ""Sixty percent of patients come to medical attention before 10 years of age, with the remainder of cases manifesting in adolescence and adulthood."", ""supports"": ""SUPPORT""}"
5093	5009	210	Melanoma_in_Congenital_Melanocytic_Nevus	Melanoma_in_Congenital_Melanocytic_Nevus.yaml	progression	0	evidence	0	PMID:28785360	SUPPORT		Although not common, the possible malignant transformation remains one of the most important considerations related to them, as the related lifetime risk of melanoma is 4% to 10%.	The abstract discusses the risk of melanoma in congenital melanocytic nevi occurring from childhood to adulthood, supporting the statement.	"{""explanation"": ""The abstract discusses the risk of melanoma in congenital melanocytic nevi occurring from childhood to adulthood, supporting the statement."", ""reference"": ""PMID:28785360"", ""snippet"": ""Although not common, the possible malignant transformation remains one of the most important considerations related to them, as the related lifetime risk of melanoma is 4% to 10%."", ""supports"": ""SUPPORT""}"
5412	5240	219	Multiple Sclerosis	Multiple_Sclerosis.yaml	progression	0	evidence	0	PMID:25997994	SUPPORT		Relapses (episodic exacerbations of neurological signs or symptoms) are a defining feature of relapsing-remitting multiple sclerosis (MS), the most prevalent MS phenotype.	The abstract clearly states that relapses are a defining feature of relapsing-remitting MS, supporting the statement about periods of neurological symptoms followed by partial or complete recovery.	"{""explanation"": ""The abstract clearly states that relapses are a defining feature of relapsing-remitting MS, supporting the statement about periods of neurological symptoms followed by partial or complete recovery."", ""reference"": ""PMID:25997994"", ""snippet"": ""Relapses (episodic exacerbations of neurological signs or symptoms) are a defining feature of relapsing-remitting multiple sclerosis (MS), the most prevalent MS phenotype."", ""supports"": ""SUPPORT""}"
5413	5240	219	Multiple Sclerosis	Multiple_Sclerosis.yaml	progression	0	evidence	1	PMID:34006674	SUPPORT		The relapsing-remitting type is a major clinical course in MS.	This reference confirms that the relapsing-remitting type is a major clinical course in MS, aligning with the statement about periods of relapses and remissions.	"{""explanation"": ""This reference confirms that the relapsing-remitting type is a major clinical course in MS, aligning with the statement about periods of relapses and remissions."", ""reference"": ""PMID:34006674"", ""snippet"": ""The relapsing-remitting type is a major clinical course in MS."", ""supports"": ""SUPPORT""}"
5414	5240	219	Multiple Sclerosis	Multiple_Sclerosis.yaml	progression	0	evidence	2	PMID:31971066	SUPPORT		Cognitive impairment is common in multiple sclerosis (MS) but its manifestation as acute disease activity is underappreciated... In RG patients, SDMT declined from 55.2 to 44.6 at relapse and recovered to 51.7.	This study highlights cognitive function decline during relapses and subsequent recovery, supporting the characterization of MS by periods of neurological symptoms followed by recovery.	"{""explanation"": ""This study highlights cognitive function decline during relapses and subsequent recovery, supporting the characterization of MS by periods of neurological symptoms followed by recovery."", ""reference"": ""PMID:31971066"", ""snippet"": ""Cognitive impairment is common in multiple sclerosis (MS) but its manifestation as acute disease activity is underappreciated... In RG patients, SDMT declined from 55.2 to 44.6 at relapse and recovered to 51.7."", ""supports"": ""SUPPORT""}"
5415	5241	219	Multiple Sclerosis	Multiple_Sclerosis.yaml	progression	1	evidence	0	PMID:16545751	SUPPORT		The secondary progressive phase of multiple sclerosis (MS), which is characterised by a steady accrual of fixed disability after an initial relapsing remitting course, is not clearly understood.	The reference describes secondary progressive MS as a phase that follows an initial relapsing-remitting course and is characterized by progressive worsening of neurological function.	"{""explanation"": ""The reference describes secondary progressive MS as a phase that follows an initial relapsing-remitting course and is characterized by progressive worsening of neurological function."", ""reference"": ""PMID:16545751"", ""snippet"": ""The secondary progressive phase of multiple sclerosis (MS), which is characterised by a steady accrual of fixed disability after an initial relapsing remitting course, is not clearly understood."", ""supports"": ""SUPPORT""}"
5416	5241	219	Multiple Sclerosis	Multiple_Sclerosis.yaml	progression	1	evidence	1	PMID:20946934	SUPPORT		This transforms into a disease of continuous and irreversible neurological decline by the sixth or seventh decade.	The reference supports the statement by describing the transition from an initial phase with reversible episodes to a phase of continuous and irreversible neurological decline.	"{""explanation"": ""The reference supports the statement by describing the transition from an initial phase with reversible episodes to a phase of continuous and irreversible neurological decline."", ""reference"": ""PMID:20946934"", ""snippet"": ""This transforms into a disease of continuous and irreversible neurological decline by the sixth or seventh decade."", ""supports"": ""SUPPORT""}"
5417	5241	219	Multiple Sclerosis	Multiple_Sclerosis.yaml	progression	1	evidence	2	PMID:24722325	SUPPORT		The predominant clinical disease course of multiple sclerosis starts with reversible episodes of neurological disability, which transforms into progressive neurological decline.	The reference supports the statement by describing the progression from relapsing episodes to a phase of progressive neurological decline.	"{""explanation"": ""The reference supports the statement by describing the progression from relapsing episodes to a phase of progressive neurological decline."", ""reference"": ""PMID:24722325"", ""snippet"": ""The predominant clinical disease course of multiple sclerosis starts with reversible episodes of neurological disability, which transforms into progressive neurological decline."", ""supports"": ""SUPPORT""}"
5418	5242	219	Multiple Sclerosis	Multiple_Sclerosis.yaml	progression	2	evidence	0	PMID:33578205	SUPPORT		Patients with primary progressive multiple sclerosis (PPMS) vary in the rate of disability progression.	The statement describes a gradual progression of disability from onset without early relapses and remissions, which aligns with the characteristics of primary progressive MS (PPMS).	"{""explanation"": ""The statement describes a gradual progression of disability from onset without early relapses and remissions, which aligns with the characteristics of primary progressive MS (PPMS)."", ""reference"": ""PMID:33578205"", ""snippet"": ""Patients with primary progressive multiple sclerosis (PPMS) vary in the rate of disability progression."", ""supports"": ""SUPPORT""}"
5419	5242	219	Multiple Sclerosis	Multiple_Sclerosis.yaml	progression	2	evidence	1	PMID:35977131	SUPPORT		Types of MS include relapsing-remitting (most common), secondary progressive, and primary progressive.	This reference supports the classification of MS into types, including primary progressive MS, which is characterized by a gradual progression of disability from onset without early relapses and remissions.	"{""explanation"": ""This reference supports the classification of MS into types, including primary progressive MS, which is characterized by a gradual progression of disability from onset without early relapses and remissions."", ""reference"": ""PMID:35977131"", ""snippet"": ""Types of MS include relapsing-remitting (most common), secondary progressive, and primary progressive."", ""supports"": ""SUPPORT""}"
5420	5242	219	Multiple Sclerosis	Multiple_Sclerosis.yaml	progression	2	evidence	2	PMID:29157397	SUPPORT		Subclinical activity in radiologically isolated syndrome evolving to primary-progressive MS is mostly indistinguishable from relapsing-remitting MS evolving to secondary-progressive MS.	This reference supports the concept of primary progressive MS, which involves a gradual progression of disability without the early relapses and remissions seen in relapsing-remitting MS.	"{""explanation"": ""This reference supports the concept of primary progressive MS, which involves a gradual progression of disability without the early relapses and remissions seen in relapsing-remitting MS."", ""reference"": ""PMID:29157397"", ""snippet"": ""Subclinical activity in radiologically isolated syndrome evolving to primary-progressive MS is mostly indistinguishable from relapsing-remitting MS evolving to secondary-progressive MS."", ""supports"": ""SUPPORT""}"
5421	5243	219	Multiple Sclerosis	Multiple_Sclerosis.yaml	progression	3	evidence	0	PMID:37068931	NO_EVIDENCE		BACKGROUND: Some studies comparing primary and secondary progressive multiple sclerosis (PPMS, SPMS) report similar ages at onset of the progressive phase and similar rates of subsequent disability accrual. Others report later onset and/or faster accrual in SPMS.	The reference discusses primary and secondary progressive multiple sclerosis but does not mention progressive-relapsing multiple sclerosis (PRMS).	"{""explanation"": ""The reference discusses primary and secondary progressive multiple sclerosis but does not mention progressive-relapsing multiple sclerosis (PRMS)."", ""reference"": ""PMID:37068931"", ""snippet"": ""BACKGROUND: Some studies comparing primary and secondary progressive multiple sclerosis (PPMS, SPMS) report similar ages at onset of the progressive phase and similar rates of subsequent disability accrual. Others report later onset and/or faster accrual in SPMS."", ""supports"": ""NO_EVIDENCE""}"
5422	5243	219	Multiple Sclerosis	Multiple_Sclerosis.yaml	progression	3	evidence	1	PMID:17884680	NO_EVIDENCE		About 10-15% of patients with multiple sclerosis (MS) present with gradually increasing neurological disability, a disorder known as primary-progressive multiple sclerosis (PPMS).	This reference focuses on primary-progressive multiple sclerosis (PPMS) and does not address progressive-relapsing multiple sclerosis (PRMS).	"{""explanation"": ""This reference focuses on primary-progressive multiple sclerosis (PPMS) and does not address progressive-relapsing multiple sclerosis (PRMS)."", ""reference"": ""PMID:17884680"", ""snippet"": ""About 10-15% of patients with multiple sclerosis (MS) present with gradually increasing neurological disability, a disorder known as primary-progressive multiple sclerosis (PPMS)."", ""supports"": ""NO_EVIDENCE""}"
5423	5243	219	Multiple Sclerosis	Multiple_Sclerosis.yaml	progression	3	evidence	2	PMID:31397221	NO_EVIDENCE		BACKGROUND: The risk factors for conversion from relapsing-remitting to secondary progressive multiple sclerosis remain highly contested.	The reference discusses the transition from relapsing-remitting to secondary progressive multiple sclerosis but does not mention progressive-relapsing multiple sclerosis (PRMS).	"{""explanation"": ""The reference discusses the transition from relapsing-remitting to secondary progressive multiple sclerosis but does not mention progressive-relapsing multiple sclerosis (PRMS)."", ""reference"": ""PMID:31397221"", ""snippet"": ""BACKGROUND: The risk factors for conversion from relapsing-remitting to secondary progressive multiple sclerosis remain highly contested."", ""supports"": ""NO_EVIDENCE""}"
5424	5243	219	Multiple Sclerosis	Multiple_Sclerosis.yaml	progression	3	evidence	3	PMID:11207871	NO_EVIDENCE		Late-onset MS was defined as the first presentation of clinical symptoms after the age of 50 years.	The reference discusses late-onset multiple sclerosis but does not specifically address progressive-relapsing multiple sclerosis (PRMS).	"{""explanation"": ""The reference discusses late-onset multiple sclerosis but does not specifically address progressive-relapsing multiple sclerosis (PRMS)."", ""reference"": ""PMID:11207871"", ""snippet"": ""Late-onset MS was defined as the first presentation of clinical symptoms after the age of 50 years."", ""supports"": ""NO_EVIDENCE""}"
5425	5243	219	Multiple Sclerosis	Multiple_Sclerosis.yaml	progression	3	evidence	4	PMID:24722325	NO_EVIDENCE		The clinical course of multiple sclerosis is variable, and the disease can be classified into relapsing and progressive phases.	The reference distinguishes between relapsing and progressive phases of multiple sclerosis but does not specifically mention progressive-relapsing multiple sclerosis (PRMS).	"{""explanation"": ""The reference distinguishes between relapsing and progressive phases of multiple sclerosis but does not specifically mention progressive-relapsing multiple sclerosis (PRMS)."", ""reference"": ""PMID:24722325"", ""snippet"": ""The clinical course of multiple sclerosis is variable, and the disease can be classified into relapsing and progressive phases."", ""supports"": ""NO_EVIDENCE""}"
5508	5290	220	Multisystem Inflammatory Syndrome in Children (MIS-C)	Multisystem_Inflammatory_Syndrome_in_Children_MIS-C.yaml	progression	0	evidence	0	PMID:36881797	PARTIAL		Multisystem inflammatory disease in children (MIS-C) is a condition typically seen 3 to 6 weeks after acute infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).	The reference supports the timing of onset (2-6 weeks after COVID-19 infection) but does not specify the age range 0-21. It mentions children, which generally refers to individuals under 18.	"{""explanation"": ""The reference supports the timing of onset (2-6 weeks after COVID-19 infection) but does not specify the age range 0-21. It mentions children, which generally refers to individuals under 18."", ""reference"": ""PMID:36881797"", ""snippet"": ""Multisystem inflammatory disease in children (MIS-C) is a condition typically seen 3 to 6 weeks after acute infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)."", ""supports"": ""PARTIAL""}"
5509	5290	220	Multisystem Inflammatory Syndrome in Children (MIS-C)	Multisystem_Inflammatory_Syndrome_in_Children_MIS-C.yaml	progression	0	evidence	1	PMID:35288706	NO_EVIDENCE		Comparing paediatric COVID-19 with MIS-C.	The title suggests a comparison study but does not provide specific evidence related to the age range or onset timing.	"{""explanation"": ""The title suggests a comparison study but does not provide specific evidence related to the age range or onset timing."", ""reference"": ""PMID:35288706"", ""snippet"": ""Comparing paediatric COVID-19 with MIS-C."", ""supports"": ""NO_EVIDENCE""}"
5510	5290	220	Multisystem Inflammatory Syndrome in Children (MIS-C)	Multisystem_Inflammatory_Syndrome_in_Children_MIS-C.yaml	progression	0	evidence	2	PMID:34311990	PARTIAL		Nevertheless, cases of severe disease or a post-infectious multisystem hyperinflammatory syndrome named multisystem inflammatory syndrome in children (MIS-C) have been described.	The reference mentions MIS-C as a post-infectious condition but does not specify the age range 0-21 or the exact timing of onset.	"{""explanation"": ""The reference mentions MIS-C as a post-infectious condition but does not specify the age range 0-21 or the exact timing of onset."", ""reference"": ""PMID:34311990"", ""snippet"": ""Nevertheless, cases of severe disease or a post-infectious multisystem hyperinflammatory syndrome named multisystem inflammatory syndrome in children (MIS-C) have been described."", ""supports"": ""PARTIAL""}"
5511	5290	220	Multisystem Inflammatory Syndrome in Children (MIS-C)	Multisystem_Inflammatory_Syndrome_in_Children_MIS-C.yaml	progression	0	evidence	3	PMID:37142896	PARTIAL		Children may develop a specific complication of COVID-19 called multisystem inflammatory syndrome in children (MIS-C) which could influence the vascular system of children and cause multiple coagulopathies in the body.	The reference supports the occurrence of MIS-C in children but does not specify the age range 0-21 or the exact timing of onset.	"{""explanation"": ""The reference supports the occurrence of MIS-C in children but does not specify the age range 0-21 or the exact timing of onset."", ""reference"": ""PMID:37142896"", ""snippet"": ""Children may develop a specific complication of COVID-19 called multisystem inflammatory syndrome in children (MIS-C) which could influence the vascular system of children and cause multiple coagulopathies in the body."", ""supports"": ""PARTIAL""}"
5512	5290	220	Multisystem Inflammatory Syndrome in Children (MIS-C)	Multisystem_Inflammatory_Syndrome_in_Children_MIS-C.yaml	progression	0	evidence	4	PMID:32525700	PARTIAL		Multisystem Inflammatory Syndrome in Children in Association With COVID-19.	The title suggests an association with COVID-19 but does not provide specific details on the age range or timing of onset.	"{""explanation"": ""The title suggests an association with COVID-19 but does not provide specific details on the age range or timing of onset."", ""reference"": ""PMID:32525700"", ""snippet"": ""Multisystem Inflammatory Syndrome in Children in Association With COVID-19."", ""supports"": ""PARTIAL""}"
5513	5290	220	Multisystem Inflammatory Syndrome in Children (MIS-C)	Multisystem_Inflammatory_Syndrome_in_Children_MIS-C.yaml	progression	0	evidence	5	PMID:35258639	PARTIAL		Multisystem inflammatory syndrome in children occurs weeks after initial infection with SARS-CoV-2 and can be associated with severe cardiovascular complications and death.	The reference supports the timing of onset (weeks after infection) but does not specify the age range 0-21.	"{""explanation"": ""The reference supports the timing of onset (weeks after infection) but does not specify the age range 0-21."", ""reference"": ""PMID:35258639"", ""snippet"": ""Multisystem inflammatory syndrome in children occurs weeks after initial infection with SARS-CoV-2 and can be associated with severe cardiovascular complications and death."", ""supports"": ""PARTIAL""}"
5514	5290	220	Multisystem Inflammatory Syndrome in Children (MIS-C)	Multisystem_Inflammatory_Syndrome_in_Children_MIS-C.yaml	progression	0	evidence	6	PMID:35183528	PARTIAL		Since the COVID-19 pandemic began, a cohort of Multisystem inflammatory syndrome in children (MIS-C) patients has been described.	The reference mentions MIS-C in children but does not specify the age range 0-21 or the exact timing of onset.	"{""explanation"": ""The reference mentions MIS-C in children but does not specify the age range 0-21 or the exact timing of onset."", ""reference"": ""PMID:35183528"", ""snippet"": ""Since the COVID-19 pandemic began, a cohort of Multisystem inflammatory syndrome in children (MIS-C) patients has been described."", ""supports"": ""PARTIAL""}"
5515	5290	220	Multisystem Inflammatory Syndrome in Children (MIS-C)	Multisystem_Inflammatory_Syndrome_in_Children_MIS-C.yaml	progression	0	evidence	7	PMID:34302327	PARTIAL		We enrolled all hospitalized children aged 1 month - 18 years and diagnosed with either MIS-C and/or dengue fever according to WHO criteria between June and December, 2020.	The reference supports the age range up to 18 years but does not include the full range 0-21 or the timing of onset.	"{""explanation"": ""The reference supports the age range up to 18 years but does not include the full range 0-21 or the timing of onset."", ""reference"": ""PMID:34302327"", ""snippet"": ""We enrolled all hospitalized children aged 1 month - 18 years and diagnosed with either MIS-C and/or dengue fever according to WHO criteria between June and December, 2020."", ""supports"": ""PARTIAL""}"
5516	5290	220	Multisystem Inflammatory Syndrome in Children (MIS-C)	Multisystem_Inflammatory_Syndrome_in_Children_MIS-C.yaml	progression	0	evidence	8	PMID:37054392	PARTIAL		This study, utilizing national data sources, describes the NZ incidence of multisystem inflammatory syndrome in children (MIS-C) following infection with the Omicron variant.	The reference supports the occurrence of MIS-C following COVID-19 infection but does not specify the age range 0-21 or the exact timing of onset.	"{""explanation"": ""The reference supports the occurrence of MIS-C following COVID-19 infection but does not specify the age range 0-21 or the exact timing of onset."", ""reference"": ""PMID:37054392"", ""snippet"": ""This study, utilizing national data sources, describes the NZ incidence of multisystem inflammatory syndrome in children (MIS-C) following infection with the Omicron variant."", ""supports"": ""PARTIAL""}"
5517	5290	220	Multisystem Inflammatory Syndrome in Children (MIS-C)	Multisystem_Inflammatory_Syndrome_in_Children_MIS-C.yaml	progression	0	evidence	9	PMID:33184170	PARTIAL		Multisystem inflammatory syndrome in children (MIS-C) has spread through the pediatric population during the coronavirus disease 2019 pandemic.	The reference supports the occurrence of MIS-C in the pediatric population but does not specify the age range 0-21 or the exact timing of onset.	"{""explanation"": ""The reference supports the occurrence of MIS-C in the pediatric population but does not specify the age range 0-21 or the exact timing of onset."", ""reference"": ""PMID:33184170"", ""snippet"": ""Multisystem inflammatory syndrome in children (MIS-C) has spread through the pediatric population during the coronavirus disease 2019 pandemic."", ""supports"": ""PARTIAL""}"
5803	5598	235	Non-Small Cell Lung Cancer	Non-Small_Cell_Lung_Cancer.yaml	progression	0	evidence	0	PMID:15477641	NO_EVIDENCE		What is clear is that currently over 50% of all patients with non-small cell lung cancer (NSCLC) are 65 years of age or older.	The study mentions the prevalence of NSCLC in patients aged 65 and older, but it does not directly address disease progression specifically in the 60-80 age range at the onset phase.	"{""explanation"": ""The study mentions the prevalence of NSCLC in patients aged 65 and older, but it does not directly address disease progression specifically in the 60-80 age range at the onset phase."", ""reference"": ""PMID:15477641"", ""snippet"": ""What is clear is that currently over 50% of all patients with non-small cell lung cancer (NSCLC) are 65 years of age or older."", ""supports"": ""NO_EVIDENCE""}"
5804	5598	235	Non-Small Cell Lung Cancer	Non-Small_Cell_Lung_Cancer.yaml	progression	0	evidence	1	PMID:20471184	NO_EVIDENCE		To assess rate of disease progression from diagnosis to initiation of treatment for Stage I-IIIB non-small-cell lung cancer (NSCLC).	This study addresses the rate of disease progression from diagnosis to treatment initiation rather than focusing on age-specific progression at onset.	"{""explanation"": ""This study addresses the rate of disease progression from diagnosis to treatment initiation rather than focusing on age-specific progression at onset."", ""reference"": ""PMID:20471184"", ""snippet"": ""To assess rate of disease progression from diagnosis to initiation of treatment for Stage I-IIIB non-small-cell lung cancer (NSCLC)."", ""supports"": ""NO_EVIDENCE""}"
5805	5598	235	Non-Small Cell Lung Cancer	Non-Small_Cell_Lung_Cancer.yaml	progression	0	evidence	2	PMID:38377969	NO_EVIDENCE		The objective of this study was to model multiple sclerosis (MS) disease progression and compare disease trajectories by sex, age of onset, and year of diagnosis.	The study focuses on multiple sclerosis and not on non-small cell lung cancer.	"{""explanation"": ""The study focuses on multiple sclerosis and not on non-small cell lung cancer."", ""reference"": ""PMID:38377969"", ""snippet"": ""The objective of this study was to model multiple sclerosis (MS) disease progression and compare disease trajectories by sex, age of onset, and year of diagnosis."", ""supports"": ""NO_EVIDENCE""}"
5806	5598	235	Non-Small Cell Lung Cancer	Non-Small_Cell_Lung_Cancer.yaml	progression	0	evidence	3	PMID:37681230	NO_EVIDENCE		Adenosquamous carcinoma of the lung is a characteristic tumor that has both adenocarcinoma and squamous cell carcinoma components.	This study focuses on adenosquamous carcinoma and does not address age-specific progression of NSCLC in the 60-80 age range specifically at onset.	"{""explanation"": ""This study focuses on adenosquamous carcinoma and does not address age-specific progression of NSCLC in the 60-80 age range specifically at onset."", ""reference"": ""PMID:37681230"", ""snippet"": ""Adenosquamous carcinoma of the lung is a characteristic tumor that has both adenocarcinoma and squamous cell carcinoma components."", ""supports"": ""NO_EVIDENCE""}"
5807	5598	235	Non-Small Cell Lung Cancer	Non-Small_Cell_Lung_Cancer.yaml	progression	0	evidence	4	PMID:34911717	NO_EVIDENCE		To assess clinicopathological predictors and prognosis in early-onset colorectal cancer (CRC) in Lynch syndrome with comparison to patients diagnosed from age 40 and up.	The study is about early-onset colorectal cancer in patients with Lynch syndrome and is not related to NSCLC.	"{""explanation"": ""The study is about early-onset colorectal cancer in patients with Lynch syndrome and is not related to NSCLC."", ""reference"": ""PMID:34911717"", ""snippet"": ""To assess clinicopathological predictors and prognosis in early-onset colorectal cancer (CRC) in Lynch syndrome with comparison to patients diagnosed from age 40 and up."", ""supports"": ""NO_EVIDENCE""}"
5808	5598	235	Non-Small Cell Lung Cancer	Non-Small_Cell_Lung_Cancer.yaml	progression	0	evidence	5	PMID:26729443	NO_EVIDENCE		Non-small-cell lung cancers (NSCLCs) harboring mutations in MET exon 14 and its flanking introns may respond to c-Met inhibitors.	While the study addresses genomic characteristics and treatment responses for NSCLC with MET exon 14 mutations, it does not specifically discuss disease progression at onset in the 60-80 age range.	"{""explanation"": ""While the study addresses genomic characteristics and treatment responses for NSCLC with MET exon 14 mutations, it does not specifically discuss disease progression at onset in the 60-80 age range."", ""reference"": ""PMID:26729443"", ""snippet"": ""Non-small-cell lung cancers (NSCLCs) harboring mutations in MET exon 14 and its flanking introns may respond to c-Met inhibitors."", ""supports"": ""NO_EVIDENCE""}"
5809	5598	235	Non-Small Cell Lung Cancer	Non-Small_Cell_Lung_Cancer.yaml	progression	0	evidence	6	PMID:29432718	NO_EVIDENCE		Among patients with previous lung cancer, the malignant potential of subsequent ground-glass opacities (GGOs) on computed tomography remains unknown.	The study examines ground-glass opacities among patients with a history of lung cancer, not specifically the progression of NSCLC in the 60-80 age range at onset.	"{""explanation"": ""The study examines ground-glass opacities among patients with a history of lung cancer, not specifically the progression of NSCLC in the 60-80 age range at onset."", ""reference"": ""PMID:29432718"", ""snippet"": ""Among patients with previous lung cancer, the malignant potential of subsequent ground-glass opacities (GGOs) on computed tomography remains unknown."", ""supports"": ""NO_EVIDENCE""}"
6356	6185	261	Pick Disease	Pick_Disease.yaml	progression	0	evidence	0	PMID:32333004	REFUTE		It can occur at any age, but most patients develop the disease between the age of 40 to 50 years.	The onset of systemic sclerosis is mentioned to occur between the ages of 40-50, which suggests that many cases do not fall within the 40-65 range exclusively for progression.	"{""explanation"": ""The onset of systemic sclerosis is mentioned to occur between the ages of 40-50, which suggests that many cases do not fall within the 40-65 range exclusively for progression."", ""reference"": ""PMID:32333004"", ""snippet"": ""It can occur at any age, but most patients develop the disease between the age of 40 to 50 years."", ""supports"": ""REFUTE""}"
6357	6185	261	Pick Disease	Pick_Disease.yaml	progression	0	evidence	1	PMID:19415691	REFUTE		Although age of onset varied significantly, the rate of progression appeared linear, independent of age of onset, and similar in all patients.	The disease Niemann-Pick type C progression appears linear and independent of age of onset, suggesting that age between 40-65 is not particularly relevant for progression. This contradicts the statement's implication of age-specific progression.	"{""explanation"": ""The disease Niemann-Pick type C progression appears linear and independent of age of onset, suggesting that age between 40-65 is not particularly relevant for progression. This contradicts the statement's implication of age-specific progression."", ""reference"": ""PMID:19415691"", ""snippet"": ""Although age of onset varied significantly, the rate of progression appeared linear, independent of age of onset, and similar in all patients."", ""supports"": ""REFUTE""}"
6358	6185	261	Pick Disease	Pick_Disease.yaml	progression	0	evidence	2	PMID:10908910	SUPPORT		Patients with disease onset between 40 and 59 years used a walker after 10.2 +/- 5.8 years, whereas those with disease onset between 60 and 79 years used a walker after 5.7 +/- 5.0 years.	There is a clear distinction in disease progression based on age of onset, indicating that progression characteristics might indeed differ across specific age ranges.	"{""explanation"": ""There is a clear distinction in disease progression based on age of onset, indicating that progression characteristics might indeed differ across specific age ranges."", ""reference"": ""PMID:10908910"", ""snippet"": ""Patients with disease onset between 40 and 59 years used a walker after 10.2 +/- 5.8 years, whereas those with disease onset between 60 and 79 years used a walker after 5.7 +/- 5.0 years."", ""supports"": ""SUPPORT""}"
6619	6454	275	Primary_Tonsillar_Lymphoma	Primary_Tonsillar_Lymphoma.yaml	progression	0	evidence	0	PMID:10592134	SUPPORT		We report six cases of primary tonsillar lymphoma with a median patient age of 42 years.	The median age of 42 years falls into the mid-adult range, supporting the age range aspect of the statement.	"{""explanation"": ""The median age of 42 years falls into the mid-adult range, supporting the age range aspect of the statement."", ""reference"": ""PMID:10592134"", ""snippet"": ""We report six cases of primary tonsillar lymphoma with a median patient age of 42 years."", ""supports"": ""SUPPORT""}"
6620	6454	275	Primary_Tonsillar_Lymphoma	Primary_Tonsillar_Lymphoma.yaml	progression	0	evidence	1	PMID:33091144	SUPPORT		An 81-year-old man presented with persistent odynophagia, dysphagia, and obstructive hypertrophic palatine tonsils with purulent exudate.	The patient's age of 81 years supports the elderly aspect of the statement.	"{""explanation"": ""The patient's age of 81 years supports the elderly aspect of the statement."", ""reference"": ""PMID:33091144"", ""snippet"": ""An 81-year-old man presented with persistent odynophagia, dysphagia, and obstructive hypertrophic palatine tonsils with purulent exudate."", ""supports"": ""SUPPORT""}"
6621	6454	275	Primary_Tonsillar_Lymphoma	Primary_Tonsillar_Lymphoma.yaml	progression	0	evidence	2	PMID:29571929	PARTIAL		The Surveillance, Epidemiology and End Results 18 database included 138 pediatric patients with tonsil cancer with an age-adjusted incidence rate of 0.021/100 000 patients per year.	This reference primarily discusses pediatric cases, which does not support the age range of mid-adult to elderly. However, it mentions rapid tonsillar enlargement, which partially supports the statement.	"{""explanation"": ""This reference primarily discusses pediatric cases, which does not support the age range of mid-adult to elderly. However, it mentions rapid tonsillar enlargement, which partially supports the statement."", ""reference"": ""PMID:29571929"", ""snippet"": ""The Surveillance, Epidemiology and End Results 18 database included 138 pediatric patients with tonsil cancer with an age-adjusted incidence rate of 0.021/100 000 patients per year."", ""supports"": ""PARTIAL""}"
6622	6455	275	Primary_Tonsillar_Lymphoma	Primary_Tonsillar_Lymphoma.yaml	progression	1	evidence	0	PMID:16613685	PARTIAL		Most patients with NHL of the tonsil are at early stages, with good prognosis.	The literature supports that primary tonsillar lymphoma is often at an early stage (localized), but it specifically mentions the tonsils and not the oropharynx or nearby lymph nodes.	"{""explanation"": ""The literature supports that primary tonsillar lymphoma is often at an early stage (localized), but it specifically mentions the tonsils and not the oropharynx or nearby lymph nodes."", ""reference"": ""PMID:16613685"", ""snippet"": ""Most patients with NHL of the tonsil are at early stages, with good prognosis."", ""supports"": ""PARTIAL""}"
6623	6456	275	Primary_Tonsillar_Lymphoma	Primary_Tonsillar_Lymphoma.yaml	progression	2	evidence	0	PMID:16613685	PARTIAL		Stage I-II patients received radiochemotherapy-predominant treatment, whereas stage III-IV patients received chemotherapy-predominant treatment.	The study mentions treatment for advanced stages (III-IV) of primary non-Hodgkin's lymphoma of the tonsil but does not explicitly state the potential for systemic spread to distant lymph nodes and organs.	"{""explanation"": ""The study mentions treatment for advanced stages (III-IV) of primary non-Hodgkin's lymphoma of the tonsil but does not explicitly state the potential for systemic spread to distant lymph nodes and organs."", ""reference"": ""PMID:16613685"", ""snippet"": ""Stage I-II patients received radiochemotherapy-predominant treatment, whereas stage III-IV patients received chemotherapy-predominant treatment."", ""supports"": ""PARTIAL""}"
6624	6456	275	Primary_Tonsillar_Lymphoma	Primary_Tonsillar_Lymphoma.yaml	progression	2	evidence	1	PMID:36943852	SUPPORT		HPV-positive tonsil cancer patients with an advanced T stage and a positive surgical margin have a substantial risk of distant metastases.	The reference discusses the risk of distant metastasis in HPV-positive tonsil cancer, supporting the statement about the potential for systemic spread in advanced stages.	"{""explanation"": ""The reference discusses the risk of distant metastasis in HPV-positive tonsil cancer, supporting the statement about the potential for systemic spread in advanced stages."", ""reference"": ""PMID:36943852"", ""snippet"": ""HPV-positive tonsil cancer patients with an advanced T stage and a positive surgical margin have a substantial risk of distant metastases."", ""supports"": ""SUPPORT""}"
6958	6800	290	Rheumatoid Arthritis	Rheumatoid_Arthritis.yaml	progression	0	evidence	0	PMID:15588970	NO_EVIDENCE		It suggests that the term 'early rheumatoid arthritis' is not appropriate and that patients either have established rheumatoid arthritis or an undifferentiated inflammatory arthritis.	This reference argues against the categorization of 'early rheumatoid arthritis' and suggests that RA should be considered either as established or undifferentiated inflammatory arthritis, providing no evidence about the progression specifically at the onset phase.	"{""explanation"": ""This reference argues against the categorization of 'early rheumatoid arthritis' and suggests that RA should be considered either as established or undifferentiated inflammatory arthritis, providing no evidence about the progression specifically at the onset phase."", ""reference"": ""PMID:15588970"", ""snippet"": ""It suggests that the term 'early rheumatoid arthritis' is not appropriate and that patients either have established rheumatoid arthritis or an undifferentiated inflammatory arthritis."", ""supports"": ""NO_EVIDENCE""}"
6959	6800	290	Rheumatoid Arthritis	Rheumatoid_Arthritis.yaml	progression	0	evidence	1	PMID:23926091	NO_EVIDENCE		However, little is known about the characteristics of symptoms at the onset of a disease that eventually progresses to RA	This study highlights the lack of comprehensive knowledge on the characteristics and progression of RA in its earliest phases, thus providing no evidence regarding the progression of RA specifically at the onset phase.	"{""explanation"": ""This study highlights the lack of comprehensive knowledge on the characteristics and progression of RA in its earliest phases, thus providing no evidence regarding the progression of RA specifically at the onset phase."", ""reference"": ""PMID:23926091"", ""snippet"": ""However, little is known about the characteristics of symptoms at the onset of a disease that eventually progresses to RA"", ""supports"": ""NO_EVIDENCE""}"
6960	6801	290	Rheumatoid Arthritis	Rheumatoid_Arthritis.yaml	progression	1	evidence	0	PMID:29039317	SUPPORT		The disease severity increases with increase in the age and reaches to its peak in above 60 years of age (p=0.001). The pattern of progression of RA in the Pakistani patients is almost consistent with other relevant studies conducted on European and European derived populations.	This study indicates that the progression of rheumatoid arthritis increases with age and is most severe in patients above 60. This indirectly supports the statement that progression can be observed in the age range of 30-60, by confirming its increase towards the upper end of this range.	"{""explanation"": ""This study indicates that the progression of rheumatoid arthritis increases with age and is most severe in patients above 60. This indirectly supports the statement that progression can be observed in the age range of 30-60, by confirming its increase towards the upper end of this range."", ""reference"": ""PMID:29039317"", ""snippet"": ""The disease severity increases with increase in the age and reaches to its peak in above 60 years of age (p=0.001). The pattern of progression of RA in the Pakistani patients is almost consistent with other relevant studies conducted on European and European derived populations."", ""supports"": ""SUPPORT""}"
6961	6801	290	Rheumatoid Arthritis	Rheumatoid_Arthritis.yaml	progression	1	evidence	1	PMID:34894251	SUPPORT		Patients with all EORA features were more numerous with age and almost exclusively older than 65 years.	This supports the idea that progression features become more prominent with age. As such, rheumatoid arthritis progression can be inferred for the age range of 30-60.	"{""explanation"": ""This supports the idea that progression features become more prominent with age. As such, rheumatoid arthritis progression can be inferred for the age range of 30-60."", ""reference"": ""PMID:34894251"", ""snippet"": ""Patients with all EORA features were more numerous with age and almost exclusively older than 65 years."", ""supports"": ""SUPPORT""}"
6962	6801	290	Rheumatoid Arthritis	Rheumatoid_Arthritis.yaml	progression	1	evidence	2	PMID:24217093	SUPPORT		A study in the UK found the population minimum prevalence of RA is 1.16% in women and 0.44% in men.	Prevalence indicates the presence of the disease, which includes its progression over time. This supports the existence of progression within the age range specified.	"{""explanation"": ""Prevalence indicates the presence of the disease, which includes its progression over time. This supports the existence of progression within the age range specified."", ""reference"": ""PMID:24217093"", ""snippet"": ""A study in the UK found the population minimum prevalence of RA is 1.16% in women and 0.44% in men."", ""supports"": ""SUPPORT""}"
6963	6801	290	Rheumatoid Arthritis	Rheumatoid_Arthritis.yaml	progression	1	evidence	3	PMID:31899521	SUPPORT		This study demonstrates improvements in inflammatory markers over time in early RA, in line with improved treatment strategies.	The discussion about the progression of clinical and inflammatory markers over time implies that progression happens in various age groups including those within 30-60 years.	"{""explanation"": ""The discussion about the progression of clinical and inflammatory markers over time implies that progression happens in various age groups including those within 30-60 years."", ""reference"": ""PMID:31899521"", ""snippet"": ""This study demonstrates improvements in inflammatory markers over time in early RA, in line with improved treatment strategies."", ""supports"": ""SUPPORT""}"
7007	6821	291	Roifman-syndrome	Roifman-syndrome.yaml	progression	0	evidence	0	PMID:35450878	NO_EVIDENCE		Roifman syndrome is a rare autosomal recessive inherited syndromic immunodeficiency. We wish to add to the available literature by reporting two brothers with clinical, radiological and immunological features of Roifman syndrome, confirmed on whole exome sequencing.	The provided literature does not specify the age range or phase of onset for Roifman syndrome.	"{""explanation"": ""The provided literature does not specify the age range or phase of onset for Roifman syndrome."", ""reference"": ""PMID:35450878"", ""snippet"": ""Roifman syndrome is a rare autosomal recessive inherited syndromic immunodeficiency. We wish to add to the available literature by reporting two brothers with clinical, radiological and immunological features of Roifman syndrome, confirmed on whole exome sequencing."", ""supports"": ""NO_EVIDENCE""}"
7166	6942	297	Schizophrenia	Schizophrenia.yaml	progression	0	evidence	0	PMID:10225329	SUPPORT		In adolescence, preschizophrenics exhibit subtle changes in cognition and affect as well as a variety of anomalous subjective experiences (so-called 'basic symptoms'), suggesting 'trait' status of these features.	This reference indicates that during adolescence, which overlaps with the 15-25 age range, individuals who are preschizophrenic show subtle changes in their thoughts and feelings, aligning with the prodromal phase as described.	"{""explanation"": ""This reference indicates that during adolescence, which overlaps with the 15-25 age range, individuals who are preschizophrenic show subtle changes in their thoughts and feelings, aligning with the prodromal phase as described."", ""reference"": ""PMID:10225329"", ""snippet"": ""In adolescence, preschizophrenics exhibit subtle changes in cognition and affect as well as a variety of anomalous subjective experiences (so-called 'basic symptoms'), suggesting 'trait' status of these features."", ""supports"": ""SUPPORT""}"
7167	6942	297	Schizophrenia	Schizophrenia.yaml	progression	0	evidence	1	PMID:37027026	SUPPORT		EOP patients had significantly more prodromal symptoms with a higher frequency of trouble with thinking, avolition and hallucinations than AOP patients.	This study supports the presence of subtle changes in thinking and behavior during the prodromal phase in early-onset psychosis, which includes patients younger than 18, blending into the 15-25 age range.	"{""explanation"": ""This study supports the presence of subtle changes in thinking and behavior during the prodromal phase in early-onset psychosis, which includes patients younger than 18, blending into the 15-25 age range."", ""reference"": ""PMID:37027026"", ""snippet"": ""EOP patients had significantly more prodromal symptoms with a higher frequency of trouble with thinking, avolition and hallucinations than AOP patients."", ""supports"": ""SUPPORT""}"
7168	6943	297	Schizophrenia	Schizophrenia.yaml	progression	1	evidence	0	PMID:7654792	PARTIAL		Early-onset schizophrenias (< or = 20 years) were compared with a medium-onset group (21 - < 35 years) and a late-onset group (35 - < 60 years) with regard to age and type of onset, early symptom-related course, social development and social course.	The study provides information about the age of onset and early course of schizophrenia that falls within the 16-30 age range but does not specifically address the entire age range spectrum for the onset of the first episode of psychosis.	"{""explanation"": ""The study provides information about the age of onset and early course of schizophrenia that falls within the 16-30 age range but does not specifically address the entire age range spectrum for the onset of the first episode of psychosis."", ""reference"": ""PMID:7654792"", ""snippet"": ""Early-onset schizophrenias (< or = 20 years) were compared with a medium-onset group (21 - < 35 years) and a late-onset group (35 - < 60 years) with regard to age and type of onset, early symptom-related course, social development and social course."", ""supports"": ""PARTIAL""}"
7169	6943	297	Schizophrenia	Schizophrenia.yaml	progression	1	evidence	1	PMID:20021319	SUPPORT		There are progressive frontal changes in males with adolescent-onset psychosis... Ultra high-risk patients who subsequently develop psychosis and first-episode psychosis patients develop significant grey matter reduction in the planum polare, planum temporale and caudal region; a progressive process in the superior temporal gyrus may precede the first expression of florid psychosis.	This literature provides evidence about the progression of schizophrenia, particularly related to brain changes, within the stated age range of 16-30 years during the onset phase of the first episode of psychosis.	"{""explanation"": ""This literature provides evidence about the progression of schizophrenia, particularly related to brain changes, within the stated age range of 16-30 years during the onset phase of the first episode of psychosis."", ""reference"": ""PMID:20021319"", ""snippet"": ""There are progressive frontal changes in males with adolescent-onset psychosis... Ultra high-risk patients who subsequently develop psychosis and first-episode psychosis patients develop significant grey matter reduction in the planum polare, planum temporale and caudal region; a progressive process in the superior temporal gyrus may precede the first expression of florid psychosis."", ""supports"": ""SUPPORT""}"
7170	6943	297	Schizophrenia	Schizophrenia.yaml	progression	1	evidence	2	PMID:10225329	SUPPORT		Prodromal symptoms occur in a substantial proportion of preschizophrenics, followed by a short prepsychotic phase with the crystallization of a psychotic syndrome.	This reference supports the progression of schizophrenia during the onset phase and includes the age group that aligns with the 16-30 age range.	"{""explanation"": ""This reference supports the progression of schizophrenia during the onset phase and includes the age group that aligns with the 16-30 age range."", ""reference"": ""PMID:10225329"", ""snippet"": ""Prodromal symptoms occur in a substantial proportion of preschizophrenics, followed by a short prepsychotic phase with the crystallization of a psychotic syndrome."", ""supports"": ""SUPPORT""}"
7171	6943	297	Schizophrenia	Schizophrenia.yaml	progression	1	evidence	3	PMID:26467909	PARTIAL		Patients with first-episode psychosis were found to have high relapse rates during the first years after illness onset.	While discussing the progression of symptoms and outcomes following the first episode of psychosis, this study does not focus specifically on the age range of 16-30 years.	"{""explanation"": ""While discussing the progression of symptoms and outcomes following the first episode of psychosis, this study does not focus specifically on the age range of 16-30 years."", ""reference"": ""PMID:26467909"", ""snippet"": ""Patients with first-episode psychosis were found to have high relapse rates during the first years after illness onset."", ""supports"": ""PARTIAL""}"
7172	6944	297	Schizophrenia	Schizophrenia.yaml	progression	2	evidence	0	PMID:9789265	SUPPORT		Long-term treatment of patients with chronic schizophrenias requires integration of many therapeutic approaches, co-operation of several professions, and regard for the views of patients and relatives.	The excerpt supports the idea that managing symptoms and functioning in chronic schizophrenia requires long-term management.	"{""explanation"": ""The excerpt supports the idea that managing symptoms and functioning in chronic schizophrenia requires long-term management."", ""reference"": ""PMID:9789265"", ""snippet"": ""Long-term treatment of patients with chronic schizophrenias requires integration of many therapeutic approaches, co-operation of several professions, and regard for the views of patients and relatives."", ""supports"": ""SUPPORT""}"
7173	6944	297	Schizophrenia	Schizophrenia.yaml	progression	2	evidence	1	PMID:23172002	PARTIAL		The evidence shows that although approximately 25% of people with schizophrenia have a poor long-term outcome, few of these show the incremental loss of function that is characteristic of neurodegenerative illnesses.	This statement supports the idea that while a subset of patients experience poor long-term outcomes, most do not have progressive deterioration like in neurodegenerative diseases.	"{""explanation"": ""This statement supports the idea that while a subset of patients experience poor long-term outcomes, most do not have progressive deterioration like in neurodegenerative diseases."", ""reference"": ""PMID:23172002"", ""snippet"": ""The evidence shows that although approximately 25% of people with schizophrenia have a poor long-term outcome, few of these show the incremental loss of function that is characteristic of neurodegenerative illnesses."", ""supports"": ""PARTIAL""}"
7174	6944	297	Schizophrenia	Schizophrenia.yaml	progression	2	evidence	2	PMID:10082190	SUPPORT		The criteria proposed necessitate (i) diagnosis of schizophrenia by standard operational criteria, (ii) continuous hospitalization for at least the past 2 years, (iii) a level of psychosocial functioning of < or = 40 as measured by the Global Assessment Scale, and (iv) an intensity score of 'marked' or 'severe' on at least three of the six Manchester Scale items.	The criteria for refractory schizophrenia include long-term management indicating that managing symptoms and functioning over time is essential.	"{""explanation"": ""The criteria for refractory schizophrenia include long-term management indicating that managing symptoms and functioning over time is essential."", ""reference"": ""PMID:10082190"", ""snippet"": ""The criteria proposed necessitate (i) diagnosis of schizophrenia by standard operational criteria, (ii) continuous hospitalization for at least the past 2 years, (iii) a level of psychosocial functioning of < or = 40 as measured by the Global Assessment Scale, and (iv) an intensity score of 'marked' or 'severe' on at least three of the six Manchester Scale items."", ""supports"": ""SUPPORT""}"
7175	6944	297	Schizophrenia	Schizophrenia.yaml	progression	2	evidence	3	PMID:26168930	SUPPORT		A cluster analysis performed on the resulting similarity matrix yielded two main groups (a 'improving' and a 'chronic' group), which comprised a total of six different types of illness course.	The study's finding of an 'improving' and 'chronic' group supports that managing symptoms and functioning is a significant aspect for those in the chronic phase.	"{""explanation"": ""The study's finding of an 'improving' and 'chronic' group supports that managing symptoms and functioning is a significant aspect for those in the chronic phase."", ""reference"": ""PMID:26168930"", ""snippet"": ""A cluster analysis performed on the resulting similarity matrix yielded two main groups (a 'improving' and a 'chronic' group), which comprised a total of six different types of illness course."", ""supports"": ""SUPPORT""}"
7240	6978	298	Scimitar Syndrome	Scimitar_Syndrome.yaml	progression	0	evidence	0	PMID:29054305	SUPPORT	HUMAN_CLINICAL	Overall mortality after baffle repair or scimitar vein reimplantation was 37.5% (3 of 8) for infants and 0% (0 of 6) for noninfants (p = 0.209). Overall mortality for medically managed infants was 46.7% (7 of 15) compared with 0% (0 of 8) for noninfants (p = 0.052).	Cohort study demonstrating dramatically higher mortality in infantile compared to non-infantile scimitar syndrome, whether surgically or medically managed.	"{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""Cohort study demonstrating dramatically higher mortality in infantile compared to non-infantile scimitar syndrome, whether surgically or medically managed."", ""reference"": ""PMID:29054305"", ""snippet"": ""Overall mortality after baffle repair or scimitar vein reimplantation was 37.5% (3 of 8) for infants and 0% (0 of 6) for noninfants (p = 0.209). Overall mortality for medically managed infants was 46.7% (7 of 15) compared with 0% (0 of 8) for noninfants (p = 0.052)."", ""supports"": ""SUPPORT""}"
7241	6978	298	Scimitar Syndrome	Scimitar_Syndrome.yaml	progression	0	evidence	1	PMID:41054308	SUPPORT	HUMAN_CLINICAL	We present a case of an infant with Scimitar syndrome with a well-formed right pulmonary artery, in high Qp heart failure who was managed with right pulmonary artery banding after thorough haemodynamic evaluation.	Case report of infantile scimitar syndrome with high-output heart failure requiring unconventional pulmonary artery banding, illustrating the severity of the infantile form.	"{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""Case report of infantile scimitar syndrome with high-output heart failure requiring unconventional pulmonary artery banding, illustrating the severity of the infantile form."", ""reference"": ""PMID:41054308"", ""snippet"": ""We present a case of an infant with Scimitar syndrome with a well-formed right pulmonary artery, in high Qp heart failure who was managed with right pulmonary artery banding after thorough haemodynamic evaluation."", ""supports"": ""SUPPORT""}"
7242	6979	298	Scimitar Syndrome	Scimitar_Syndrome.yaml	progression	1	evidence	0	PMID:16638549	SUPPORT	HUMAN_CLINICAL	There is a clear bimodal presentation of this syndrome with either an infantile manifestation or a pediatric/adult form. The infantile variant is marked by a higher incidence and severity of associated defects, heart failure, pulmonary hypertension, and significant mortality. The patient with the pediatric/adult form is less severely affected and may be asymptomatic on diagnosis.	Review establishing the bimodal presentation pattern, with the adult form being milder and often asymptomatic.	"{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""Review establishing the bimodal presentation pattern, with the adult form being milder and often asymptomatic."", ""reference"": ""PMID:16638549"", ""snippet"": ""There is a clear bimodal presentation of this syndrome with either an infantile manifestation or a pediatric/adult form. The infantile variant is marked by a higher incidence and severity of associated defects, heart failure, pulmonary hypertension, and significant mortality. The patient with the pediatric/adult form is less severely affected and may be asymptomatic on diagnosis."", ""supports"": ""SUPPORT""}"
7243	6979	298	Scimitar Syndrome	Scimitar_Syndrome.yaml	progression	1	evidence	1	PMID:41625718	SUPPORT	HUMAN_CLINICAL	We report the case of a 57-year-old male admitted for exertional chest pain and elevated troponin levels, initially managed as suspected MINOCA. Coronary angiography excluded obstructive coronary artery disease, while subsequent multimodality imaging unexpectedly revealed Scimitar syndrome, a rare congenital heart disease.	Case of scimitar syndrome first diagnosed at age 57 during MINOCA workup, illustrating how the adult form may remain undiagnosed for decades and present incidentally.	"{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""Case of scimitar syndrome first diagnosed at age 57 during MINOCA workup, illustrating how the adult form may remain undiagnosed for decades and present incidentally."", ""reference"": ""PMID:41625718"", ""snippet"": ""We report the case of a 57-year-old male admitted for exertional chest pain and elevated troponin levels, initially managed as suspected MINOCA. Coronary angiography excluded obstructive coronary artery disease, while subsequent multimodality imaging unexpectedly revealed Scimitar syndrome, a rare congenital heart disease."", ""supports"": ""SUPPORT""}"
7244	6979	298	Scimitar Syndrome	Scimitar_Syndrome.yaml	progression	1	evidence	2	PMID:40051748	SUPPORT	HUMAN_CLINICAL	The adult form of this rare syndrome may remain underdiagnosed for years due to its less severe clinical presentation or incidental findings, such as recurrent pulmonary infections or unexplained dyspnoea.	Case of a 24-year-old with asthma presenting with acute exacerbation, diagnosed with scimitar syndrome on CT angiography, illustrating underdiagnosis of the adult form.	"{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""Case of a 24-year-old with asthma presenting with acute exacerbation, diagnosed with scimitar syndrome on CT angiography, illustrating underdiagnosis of the adult form."", ""reference"": ""PMID:40051748"", ""snippet"": ""The adult form of this rare syndrome may remain underdiagnosed for years due to its less severe clinical presentation or incidental findings, such as recurrent pulmonary infections or unexplained dyspnoea."", ""supports"": ""SUPPORT""}"
7756	7507	327	Transient Neonatal Pustular Melanosis	Transient_Neonatal_Pustular_Melanosis.yaml	progression	0	evidence	0	PMID:33609325	SUPPORT		In this study, newborns born between 2018 and 2019 were evaluated prospectively. Along with demographic findings, temporary neonatal skin manifestations, congenital spots, benign neonatal pustulosis, congenital anomalies and other lesions were statistically evaluated.	The reference specifies the evaluation of neonatal skin manifestations in newborns, including Transient Neonatal Pustular Melanosis, thus supporting the statement about its onset phase at birth.	"{""explanation"": ""The reference specifies the evaluation of neonatal skin manifestations in newborns, including Transient Neonatal Pustular Melanosis, thus supporting the statement about its onset phase at birth."", ""reference"": ""PMID:33609325"", ""snippet"": ""In this study, newborns born between 2018 and 2019 were evaluated prospectively. Along with demographic findings, temporary neonatal skin manifestations, congenital spots, benign neonatal pustulosis, congenital anomalies and other lesions were statistically evaluated."", ""supports"": ""SUPPORT""}"
7757	7507	327	Transient Neonatal Pustular Melanosis	Transient_Neonatal_Pustular_Melanosis.yaml	progression	0	evidence	1	PMID:11422167	SUPPORT		It must be distinguished from other causes of a pustular eruption in neonates, including infection and erythema toxicum neonatorum, and rare disorders such as transient neonatal pustular melanosis...	The article includes transient neonatal pustular melanosis in the differential diagnosis of pustular eruptions in neonates, indicating its occurrence from birth.	"{""explanation"": ""The article includes transient neonatal pustular melanosis in the differential diagnosis of pustular eruptions in neonates, indicating its occurrence from birth."", ""reference"": ""PMID:11422167"", ""snippet"": ""It must be distinguished from other causes of a pustular eruption in neonates, including infection and erythema toxicum neonatorum, and rare disorders such as transient neonatal pustular melanosis..."", ""supports"": ""SUPPORT""}"
7758	7508	327	Transient Neonatal Pustular Melanosis	Transient_Neonatal_Pustular_Melanosis.yaml	progression	1	evidence	0	PMID:22884507	NO_EVIDENCE		Transient neonatal pustular melanosis.	The reference title mentions the condition transient neonatal pustular melanosis, but it does not provide any specific information about its progression, age range, or resolution phase.	"{""explanation"": ""The reference title mentions the condition transient neonatal pustular melanosis, but it does not provide any specific information about its progression, age range, or resolution phase."", ""reference"": ""PMID:22884507"", ""snippet"": ""Transient neonatal pustular melanosis."", ""supports"": ""NO_EVIDENCE""}"
7759	7508	327	Transient Neonatal Pustular Melanosis	Transient_Neonatal_Pustular_Melanosis.yaml	progression	1	evidence	1	PMID:37340913	NO_EVIDENCE		A Neonate With a Rash.	Though discussing various neonatal conditions involving rashes, the abstract does not mention specific details about transient neonatal pustular melanosis or its progression and resolution age range.	"{""explanation"": ""Though discussing various neonatal conditions involving rashes, the abstract does not mention specific details about transient neonatal pustular melanosis or its progression and resolution age range."", ""reference"": ""PMID:37340913"", ""snippet"": ""A Neonate With a Rash."", ""supports"": ""NO_EVIDENCE""}"
7760	7508	327	Transient Neonatal Pustular Melanosis	Transient_Neonatal_Pustular_Melanosis.yaml	progression	1	evidence	2	PMID:29974501	NO_EVIDENCE		Management of afebrile neonates with pustules and vesicles in a pediatric emergency department.	The study mentions vesicles and pustules in afebrile neonates but doesn't provide information specifically about transient neonatal pustular melanosis and its progression or resolution phase.	"{""explanation"": ""The study mentions vesicles and pustules in afebrile neonates but doesn't provide information specifically about transient neonatal pustular melanosis and its progression or resolution phase."", ""reference"": ""PMID:29974501"", ""snippet"": ""Management of afebrile neonates with pustules and vesicles in a pediatric emergency department."", ""supports"": ""NO_EVIDENCE""}"
7761	7508	327	Transient Neonatal Pustular Melanosis	Transient_Neonatal_Pustular_Melanosis.yaml	progression	1	evidence	3	PMID:31553864	NO_EVIDENCE		A neonatal pustule:Langerhans cell histiocytosis.	Discusses Langerhans cell histiocytosis and its presentation in neonates, but does not cover transient neonatal pustular melanosis.	"{""explanation"": ""Discusses Langerhans cell histiocytosis and its presentation in neonates, but does not cover transient neonatal pustular melanosis."", ""reference"": ""PMID:31553864"", ""snippet"": ""A neonatal pustule:Langerhans cell histiocytosis."", ""supports"": ""NO_EVIDENCE""}"
7762	7508	327	Transient Neonatal Pustular Melanosis	Transient_Neonatal_Pustular_Melanosis.yaml	progression	1	evidence	4	PMID:11422167	NO_EVIDENCE		Neonatal eosinophilic pustular folliculitis.	Mentions eosinophilic pustular folliculitis and compares it to other pustular neonatal conditions, including transient neonatal pustular melanosis, but does not provide details on the progression, age range, or resolution phase of transient neonatal pustular melanosis.	"{""explanation"": ""Mentions eosinophilic pustular folliculitis and compares it to other pustular neonatal conditions, including transient neonatal pustular melanosis, but does not provide details on the progression, age range, or resolution phase of transient neonatal pustular melanosis."", ""reference"": ""PMID:11422167"", ""snippet"": ""Neonatal eosinophilic pustular folliculitis."", ""supports"": ""NO_EVIDENCE""}"
7892	7593	331	Tuberculosis	Tuberculosis.yaml	progression	0	evidence	0	PMID:30021818	PARTIAL		Human TB infection, from latent infection to active disease, exists within a continuous spectrum of metabolic bacterial activity and antagonistic immunological responses.	This reference supports the concept of variable progression within the latent phase but does not explicitly refer to the duration being variable or confirm the non-contagious stage where bacteria are inactive.	"{""explanation"": ""This reference supports the concept of variable progression within the latent phase but does not explicitly refer to the duration being variable or confirm the non-contagious stage where bacteria are inactive."", ""reference"": ""PMID:30021818"", ""snippet"": ""Human TB infection, from latent infection to active disease, exists within a continuous spectrum of metabolic bacterial activity and antagonistic immunological responses."", ""supports"": ""PARTIAL""}"
7893	7593	331	Tuberculosis	Tuberculosis.yaml	progression	0	evidence	1	PMID:23460007	SUPPORT		Latent tuberculosis infection (LTBI) refers to a circumstance in which viable Mycobacterium tuberculosis (MTB) bacilli are present in an individual but symptoms and signs of active disease are lacking, and the bacilli are relatively inactive metabolically.	The reference directly supports the statement that during the latent phase, tuberculosis is in a non-contagious stage where the bacteria are present but inactive.	"{""explanation"": ""The reference directly supports the statement that during the latent phase, tuberculosis is in a non-contagious stage where the bacteria are present but inactive."", ""reference"": ""PMID:23460007"", ""snippet"": ""Latent tuberculosis infection (LTBI) refers to a circumstance in which viable Mycobacterium tuberculosis (MTB) bacilli are present in an individual but symptoms and signs of active disease are lacking, and the bacilli are relatively inactive metabolically."", ""supports"": ""SUPPORT""}"
7894	7594	331	Tuberculosis	Tuberculosis.yaml	progression	1	evidence	0	PMID:30021818	SUPPORT		Recent research has clearly demonstrated that human TB infection, from latent infection to active disease, exists within a continuous spectrum of metabolic bacterial activity and antagonistic immunological responses.	This indicates the variable duration of progression from latent to active TB, supporting the statement.	"{""explanation"": ""This indicates the variable duration of progression from latent to active TB, supporting the statement."", ""reference"": ""PMID:30021818"", ""snippet"": ""Recent research has clearly demonstrated that human TB infection, from latent infection to active disease, exists within a continuous spectrum of metabolic bacterial activity and antagonistic immunological responses."", ""supports"": ""SUPPORT""}"
7895	7594	331	Tuberculosis	Tuberculosis.yaml	progression	1	evidence	1	PMID:37094782	SUPPORT		In this cohort, children and adolescents diagnosed with TB experienced symptoms for a median of 85 days (interquartile range: 30, 231 days) prior to treatment initiation.	The variable duration of symptom onset supports the statement.	"{""explanation"": ""The variable duration of symptom onset supports the statement."", ""reference"": ""PMID:37094782"", ""snippet"": ""In this cohort, children and adolescents diagnosed with TB experienced symptoms for a median of 85 days (interquartile range: 30, 231 days) prior to treatment initiation."", ""supports"": ""SUPPORT""}"
7896	7594	331	Tuberculosis	Tuberculosis.yaml	progression	1	evidence	2	PMID:35704248	SUPPORT		The system considers demographic structure coupling with the continuous development of disease stage, which is crucial for studying how aging affects tuberculosis dynamics and disease progression.	This implies that TB progression has a variable duration depending on individual factors like age.	"{""explanation"": ""This implies that TB progression has a variable duration depending on individual factors like age."", ""reference"": ""PMID:35704248"", ""snippet"": ""The system considers demographic structure coupling with the continuous development of disease stage, which is crucial for studying how aging affects tuberculosis dynamics and disease progression."", ""supports"": ""SUPPORT""}"
8044	7682	333	Type I Diabetes	Type_I_Diabetes.yaml	progression	0	evidence	0	PMID:33825933	SUPPORT		The incidence of type 1 diabetes (T1D) has been rising steadily over the last 30 years, especially among children and adolescents, with the result that the number of cases in this age group doubles every 20 years.	This study discusses the rising incidence of type 1 diabetes in children and adolescents, which aligns with the progression of T1D during childhood and adolescence.	"{""explanation"": ""This study discusses the rising incidence of type 1 diabetes in children and adolescents, which aligns with the progression of T1D during childhood and adolescence."", ""reference"": ""PMID:33825933"", ""snippet"": ""The incidence of type 1 diabetes (T1D) has been rising steadily over the last 30 years, especially among children and adolescents, with the result that the number of cases in this age group doubles every 20 years."", ""supports"": ""SUPPORT""}"
8045	7682	333	Type I Diabetes	Type_I_Diabetes.yaml	progression	0	evidence	1	PMID:30628751	PARTIAL		Twenty-one percent of subjects developed T1D by age 6. Logistic regression modeling identified 5 significant predictors.	This study focuses on predictors of T1D progression in children with high-risk HLA genes followed in The TEDDY study, providing partial support since it includes childhood but doesn't explicitly cover adolescence.	"{""explanation"": ""This study focuses on predictors of T1D progression in children with high-risk HLA genes followed in The TEDDY study, providing partial support since it includes childhood but doesn't explicitly cover adolescence."", ""reference"": ""PMID:30628751"", ""snippet"": ""Twenty-one percent of subjects developed T1D by age 6. Logistic regression modeling identified 5 significant predictors."", ""supports"": ""PARTIAL""}"
8046	7682	333	Type I Diabetes	Type_I_Diabetes.yaml	progression	0	evidence	2	PMID:20723813	NO_EVIDENCE			This reference only provides a foreword and does not include specific information about the progression phase or onset of Type 1 Diabetes.	"{""explanation"": ""This reference only provides a foreword and does not include specific information about the progression phase or onset of Type 1 Diabetes."", ""reference"": ""PMID:20723813"", ""snippet"": """", ""supports"": ""NO_EVIDENCE""}"
8047	7682	333	Type I Diabetes	Type_I_Diabetes.yaml	progression	0	evidence	3	PMID:26404926	SUPPORT		Stage 3 as onset of symptomatic disease ... Adoption of this staging classification provides a standardized taxonomy for type 1 diabetes.	This reference discusses the presymptomatic stages of T1D leading to symptomatic onset, supporting the progression during childhood and adolescence.	"{""explanation"": ""This reference discusses the presymptomatic stages of T1D leading to symptomatic onset, supporting the progression during childhood and adolescence."", ""reference"": ""PMID:26404926"", ""snippet"": ""Stage 3 as onset of symptomatic disease ... Adoption of this staging classification provides a standardized taxonomy for type 1 diabetes."", ""supports"": ""SUPPORT""}"
8048	7682	333	Type I Diabetes	Type_I_Diabetes.yaml	progression	0	evidence	4	PMID:31280235	PARTIAL		We aimed to evaluate children with type 1 diabetes (T1D) with early age at onset (EAO) for clinical, immune and metabolic features in order to identify age-related disease phenotypes.	This study focuses on early age at onset and disease phenotypes in children, but doesn't explicitly cover the entire range including adolescence.	"{""explanation"": ""This study focuses on early age at onset and disease phenotypes in children, but doesn't explicitly cover the entire range including adolescence."", ""reference"": ""PMID:31280235"", ""snippet"": ""We aimed to evaluate children with type 1 diabetes (T1D) with early age at onset (EAO) for clinical, immune and metabolic features in order to identify age-related disease phenotypes."", ""supports"": ""PARTIAL""}"
8049	7682	333	Type I Diabetes	Type_I_Diabetes.yaml	progression	0	evidence	5	PMID:33274481	NO_EVIDENCE			The reference title suggests outcomes over a 20-year period but doesn't provide specific data on the progression phase or onset of Type 1 Diabetes during childhood and adolescence in the provided abstract.	"{""explanation"": ""The reference title suggests outcomes over a 20-year period but doesn't provide specific data on the progression phase or onset of Type 1 Diabetes during childhood and adolescence in the provided abstract."", ""reference"": ""PMID:33274481"", ""snippet"": """", ""supports"": ""NO_EVIDENCE""}"
8050	7682	333	Type I Diabetes	Type_I_Diabetes.yaml	progression	0	evidence	6	PMID:26816135	SUPPORT		Type 1 diabetes accounted for 368/421 (87.4 %) patients with age of onset <18 y and 99/156 (63.5 %) of patients with onset between 19 and 25 y of age.	This study identifies the proportion of various types of diabetes in youth, including the onset of T1D in children and adolescents.	"{""explanation"": ""This study identifies the proportion of various types of diabetes in youth, including the onset of T1D in children and adolescents."", ""reference"": ""PMID:26816135"", ""snippet"": ""Type 1 diabetes accounted for 368/421 (87.4 %) patients with age of onset <18 y and 99/156 (63.5 %) of patients with onset between 19 and 25 y of age."", ""supports"": ""SUPPORT""}"
8342	7922	343	Wissler syndrome	Wissler_syndrome.yaml	progression	0	evidence	0	PMID:8150635	SUPPORT		A 20-year-old female patient with the typical signs of Wissler's subsepsis allergica (Wissler-Fanconi syndrome) is described.	This case report documents onset in a young adult.	"{""explanation"": ""This case report documents onset in a young adult."", ""reference"": ""PMID:8150635"", ""snippet"": ""A 20-year-old female patient with the typical signs of Wissler's subsepsis allergica (Wissler-Fanconi syndrome) is described."", ""supports"": ""SUPPORT""}"
8343	7922	343	Wissler syndrome	Wissler_syndrome.yaml	progression	0	evidence	1	PMID:1210460	SUPPORT		A further case of subsepsis allergica Wissler in a 35-year-old woman is reported.	This report documents adult-onset disease.	"{""explanation"": ""This report documents adult-onset disease."", ""reference"": ""PMID:1210460"", ""snippet"": ""A further case of subsepsis allergica Wissler in a 35-year-old woman is reported."", ""supports"": ""SUPPORT""}"
8344	7922	343	Wissler syndrome	Wissler_syndrome.yaml	progression	0	evidence	2	DOI:10.1007/978-3-642-94912-8_6	SUPPORT		Zunächst haben nur die Pädiater die Krankheit gesehen, neuerdings sind aber auch Fälle bei Erwachsenen bekanntgegeben worden.	The abstract notes that early reports were pediatric, with adult cases reported later.	"{""explanation"": ""The abstract notes that early reports were pediatric, with adult cases reported later."", ""reference"": ""DOI:10.1007/978-3-642-94912-8_6"", ""snippet"": ""Zunächst haben nur die Pädiater die Krankheit gesehen, neuerdings sind aber auch Fälle bei Erwachsenen bekanntgegeben worden."", ""supports"": ""SUPPORT""}"
8345	7923	343	Wissler syndrome	Wissler_syndrome.yaml	progression	1	evidence	0	PMID:3092775	SUPPORT		The long-term evolution is marked by recurrent febrile exacerbations, sometimes complicated by pericardo-myocarditis which usually resolves without sequellae.	The abstract summarizes recurrent febrile exacerbations and possible cardiac complications over time.	"{""explanation"": ""The abstract summarizes recurrent febrile exacerbations and possible cardiac complications over time."", ""reference"": ""PMID:3092775"", ""snippet"": ""The long-term evolution is marked by recurrent febrile exacerbations, sometimes complicated by pericardo-myocarditis which usually resolves without sequellae."", ""supports"": ""SUPPORT""}"
8383	7946	344	Wolf-Hirschhorn_Syndrome	Wolf-Hirschhorn_Syndrome.yaml	progression	0	evidence	0	PMID:29199884	SUPPORT		"Wolf-Hirschhorn syndrome is a rare genetic syndrome caused by a heterozygous deletion on chromosome 4p16.3 and is characterized by a ""Greek warrior helmet"" facies, hypotonia, developmental delay, seizures, structural central nervous system defects, intrauterine growth restriction, sketelal anomalies, cardiac defects, abnormal tooth development, and hearing loss."	This identifies intrauterine growth restriction, indicating antenatal onset of the syndrome.	"{""explanation"": ""This identifies intrauterine growth restriction, indicating antenatal onset of the syndrome."", ""reference"": ""PMID:29199884"", ""snippet"": ""Wolf-Hirschhorn syndrome is a rare genetic syndrome caused by a heterozygous deletion on chromosome 4p16.3 and is characterized by a \""Greek warrior helmet\"" facies, hypotonia, developmental delay, seizures, structural central nervous system defects, intrauterine growth restriction, sketelal anomalies, cardiac defects, abnormal tooth development, and hearing loss."", ""supports"": ""SUPPORT""}"
